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The epidermal growth factor receptor (EGFR) plays a pivotal role in cellular 
proliferation, differentiation and migration and is found to be overexpressed in a 
variety of tumours including the basal-like subtype of breast cancer. Despite 
decades of basic research in the HER signalling field, and many EGFR-targeted anti-
cancer drugs are used clinically, the success rate for these agents is low, particularly 
in terms of improvement of overall survival. In breast cancer, the clinical response 
rates vary between clinical studies, ranging from 6-49%, in part, depending on the 
type of breast cancer, the stage of the disease, and the treatment used. These 
marginal benefits are mainly due to insufficient patient selection, and potentially 
also due to an inadequate inhibition of HER signalling and tumour escape via 
alternate signalling routes (such as HER2/3/4/c-Met).  
 
The first objective of this work was to use an in-house semi-automated protein 
activity sensing/imaging technique, to interrogate the EGFR-centric subnetwork of 
proteins, in order to obtain better understanding of molecular factors influencing 
the therapeutic sensitivity of the EGFR network. 
 
To monitor EGFR activity in cells we use a CrkII-based biosensor (CrkII protein 
flanking with eGFP and mRFP1), which undergoes conformational changes upon 
phosphorylation of tyrosine-221 by EGFR and other receptor tyrosine kinase (RTK)s 
including c-Met and PDGFβR. This changes are detected by fluorescence lifetime 
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imaging microscopy (FLIM) combined with fluorescence resonance energy transfer 
(FRET). Using the sensor, we have conducted a high-content FLIM screen utilising a 
library of short interfering (si)RNA consist of 533 genes interconnected with EGFR 
directly or indirectly, chosen from the Human Protein Reference Database. Genes 
that modulate the EGF-induced biosensor conformational changes were identified. 
Including EGFR, we identified 22 possible targets (4.1% from the siRNA library) and 
have selected a few for further validation to establish the biological importance of 
the genes identified as primary hits. 
 
The same biosensor was also transfected using a liposome-based delivery system 
into murine models of basal-like breast cancer; and demonstrated a significant 
degree of intratumoural heterogeneity in EGFR activity, as well as the effect of 
EGFR inhibitors in situ. 
 
In the long term, the knowledge obtained in this thesis can potentially be translated 
to biomarkers that are based on a better understanding of tumour cell sensitivity to 
EGFR inhibition and may thereby suggest new combination treatments. 
 
  




AR     Amphiregulin 
BTC    Betacellulin 
Cbl    Casitas B-lymphoma 
CFP    Cyan fluorescent protein 
DEP1    Density-enhanced phosphatase-1 
DNA    Deoxyribonucleic acid 
dsRNA   Double stranded RNA 
ECL    Enhanced Chemiluminescence 
eGFP    Enhanced green fluorescent protein 
EGF(R)   Epidermal growth factor (receptor) 
EPN    Epigen 
EPR    Epiregulin 
ER     Estrogen receptor 
FBS     Fetal Bovine Serum 
FLIM    Fluorescence lifetime imaging microscopy 
FRET     Forster (or fluorescence) resonance energy transfer 
GAP     GTPase-activating protein 
GEF     Guanine nucleotide exchange factor 
GFP    Green fluorescent protein 
Grb-2   Growth factor receptor-bound protein-2 
HB-EGF   Heparin binding EGF-like growth factor 
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HCS    High content screening 
HER    Human epidermal growth factor receptor 
HGF    Hepatocyte growth factor 
HPRD   Human Protein Reference Database 
HTS    High throughput screening 
JAK     Janus kinase 
MAPK   Mitogen-activated protein kinase 
miRNA   MicroRNA 
mRFP1   Monomeric red fluorescent protein 1 
mRNA   Messenger ribonucleic acid 
MVB    Multivesicular bodies 
NRG1   Neuregulin/Heuregulin 1 
NSCLC   Non small cell lung cancer 
PBS    Phosphate buffered saline 
PCR    Polymerase chain reaction 
PEG     polyethylene glycol 
PET    Positron emission tomography 
PI3k    Phosphatidylinositol-3-kinase 
Picchu   Phosphorylation Indicator of Crk Chimeric Unit 
PKC     Protein kinase C 
PKR    Protein kinase R 
PLC    Phospholipase C 
PR     Progesterone receptor 
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PTB    Phosphotyrosine binding domain 
PTP    Protein tyrosine phosphatase 
RFP    Red fluorescent protein 
RISC    RNA-induced silencing complex 
RNase-III  Ribonuclease-III  
RNA    Ribonucleic acid 
RNAi    RNA interference 
SDS    Sodium Dodecyl Sulfate 
SDS-PAGE   SDS-Polyacrylamide Gel Electrophoresis 
SEM     Standard Error of the Mean 
SH     Src-homology 
shRNA    Short hairpin RNA 
siRNA   Small interfering RNA 
Sos    Son-of-sevenless 
STAT    Signal transducers and activator of transcription 
SUV    Standard uptake value  
TBS(T)   Tris-buffered saline (Tween-20) 
TCSPC    Time-correlated single-photon counting 
TGFα    Transforming growth factor-α 
TKI    Tyrosine kinase inhibitor 
TNBC    Triple negative breast cancer     
RTK    Receptor tyrosine kinase 
YFP    Yellow fluorescent protein  
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1.1 Overview on breast cancer 
Despite continuing research and advances in treatment, breast cancer remains the 
most common female cancer worldwide and the second leading cause of all cancer 
deaths (Ferlay, Shin et al. 2010; Malvezzi, Arfe et al. 2011). One-in-eight women 
develop breast cancer at some stage in their lifetime (Hayat, Howlader et al. 2007). 
Each year in the United Kingdom, over 47,000 women are diagnosed with breast 
cancer and the incidence rates are increasing slowly (Malvezzi, Arfe et al. 2011). 
With the improved medical management of patients, survival rates in England are 
high; with 83.3% of women diagnosed with breast cancer survive for five years 
(Statistics 2013). In 2010, women breast cancer caused 1031 deaths in the under-50 
age group reported in England and Wales, while 9259 deaths was reported for the 
over-50 age group. Breast cancer is much less common among men (10290 deaths 
(99.4%) in women comparing to 62 deaths (0.6%) in men in 2010 (Statistics 2011)), 
but often has a very high mortality rate due to late detection. 
 
Development of breast malignancy is strongly associated with certain risks such as 
age, genetic predisposition, hormonal and lifestyle factors. Breast cancer is staged 
by tumour sizes, local metastases to lymph nodes and distant metastases beyond 
the breast area (Cooper, Meng et al. 2011). Early breast cancers are treated 
primarily with surgery followed by radiotherapy. Adjuvant treatments such as 
hormone therapy (e.g. Tamoxifen), cytototoxic chemotherapy (e.g. Anthracycline), 
or molecularly targeted treatments (e.g. Trastuzumab) are often prescribed to 
avoid recurrence from micrometastases (Duffy, O'Donovan et al. 2011).  





Figure 1: Metastasis formation. 
Cellular transformation allows tumour growth and angiogenesis, follows by cell migration 
through the lymphatic channels or blood capillaries. Most circulating tumour cells are rapidly 
destroyed, but some of them survived and become trapped in the capillary beds of distant 
organs, such as lungs or liver. Extravasation followed by tumour proliferation within the organ 
parenchyma completes the metastatic process. To continue growing, the micrometastasis 
must develop a vascular network and evade destruction by host defences. The cells can then 
invade blood vessels, enter the circulation and produce additional metastases. 
 
Modified from Fidler, I. J. (2003). Nat Rev Cancer 3(6): 453-458. 
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The genetic changes of a single or a small number of cells allow uncontrollable 
growth and proliferation leading to tumour formation, followed by angiogenesis 
and metastasis via the lymphatic system or the bloodstream to distant organs (as 
illustrated in Figure 1) 
 
Metastatic breast cancer is the most advanced stage of breast cancer where cancer 
cells have spread past the breast and axillary (underarm) lymph nodes to other 
areas of the body, where they continue to grow and proliferate. The majority of 
cancer-related deaths are due to the growth of secondary metastatic tumours 
(Fidler 2003; Hunter, Crawford et al. 2008; Cooper, Meng et al. 2011). Tumour cells 
may also spread into the bloodstream without being detected in the lymphatic 
system. The most common region is the bone followed by the lung, and less 
frequently the liver and brain (Kang, Siegel et al. 2003; Minn, Gupta et al. 2005; 
Minn, Kang et al. 2005). Advanced/metastatic breast cancer is linked to a significant 
decrease in five-year survival (approximately 20%) compared with localised forms 
of the disease (Hayat, Howlader et al. 2007). 
 
In order to gain new insights into the pathological evidences behind different stages 
of breast cancer and to improve survival rates, it is important to identify the gene 
expression signature and molecular mechanisms that contribute to the 
development of the disease (van de Vijver, He et al. 2002).  
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1.2 Basal-like breast cancer 
 
Breast cancer is traditionally divided into three major subtypes by its 
histopathological features based on the expression of hormone-receptors (estrogen 
receptor (ER) and progesterone receptor (PR)), human epidermal growth factor 
receptor 2 (HER2) and grading with Ki67 staining, a nuclear marker of cell 
proliferation (Cheang, Chia et al. 2009). The subtypes are ER-PR positive luminal 
(luminal A - low proliferation; luminal B – high proliferation), HER2 amplified and 
triple-negative breast cancer (TNBC) with the absence of ER, PR, and HER2 (Cooper, 
Meng et al. 2011; Bertucci, Finetti et al. 2012). 
 
The introduction of molecular classification of breast cancer subtypes based on 
gene expression profiles and biomarker studies have yielded new prognostic and 
therapeutic information to achieve more favourable clinical outcomes (Corkery, 
Crown et al. 2009). In 2000, five molecular subtypes of breast cancer were 
recognised based on the gene expression patterns. The subtypes included normal-
like, HER2-amplified, luminal-A (low proliferation rate), luminal-B (high proliferation 
rate) and basal-like breast cancer (Perou, Sorlie et al. 2000).  
 
In addition to the gene expression differences between these subtypes; according 
to the breast cancer genomic analysis performed by Molecular Taxonomy of Breast 
Cancer International Consortium (METABRIC) which has produced a novel 
molecular classification of breast cancer population into 10 subgroups based on the 
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integrated analysis of copy number and gene expression in a discovery and 
validation set of 997 and 995 primary breast tumours, respectively, with long-term 
clinical follow-up. The basal-like tumours were found to be associated specifically to 
a chromosomal deletion event  (on chromosome 5) which may account for changes 
involving cell cycle, DNA damage repair and apoptosis (Curtis, Shah et al. 2012). 
 
These molecular features are strongly related to cancer development and 
progression. (Kao, Salari et al. 2009; Vuoriluoto, Haugen et al. 2011). Due to the 
absence of identified targets for therapies, basal subtype has a less favourable 
prognosis than the others, particularly luminal-A subtype, which has the highest 
survival rates. Basal subtypes are usually high-graded tumours, with more than 75% 
being grade III (Bertucci, Finetti et al. 2012). They are also associated with 
aggressive phenotype characterised by high cell proliferation, relatively younger 
patient age, high probability of early relapse and high risk of deaths after relapse 
(Hudis and Gianni 2011; Ishikawa, Horiguchi et al. 2011; Toft and Cryns 2011).  
 
Basal subtypes account for about 15-20% of all breast cancer and they are often 
triple-negative for ER, PR, and HER2 (Irshad, Ellis et al. 2011). These characteristics 
represent a major challenge to the survivorship care for the patients. The frequent 
triple-negativity of basal-like breast cancers does not render them candidate to 
hormonal and anti-HER2 therapies (Bertucci, Finetti et al. 2012). However, many 
basal subtypes overexpress epidermal growth factor receptor (EGFR) and 
intermediate filament cytokeratins 5/6 (CK5/6) (Nielsen, Hsu et al. 2004). Some 
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triple-negative basal-like breast cancers are also negative for both basal CK5/6 and 
EGFR, and will not respond to endocrine therapy or any available targeted agents 
(Reis-Filho, Milanezi et al. 2006). Given that EGFR is frequently (up to 57%) 
overexpressed in basal-like breast cancers (Nielsen, Hsu et al. 2004; Irshad, Ellis et 
al. 2011), a subset of breast cancer patients might demonstrate benefits from 
therapeutic approaches designed to target EGFR overexpression.  
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1.3 EGFR signalling 
 
EGFR (a.k.a. ErbB1 or HER1) is a 170kDa transmembrane glycoprotein that straddles 
the cell membrane. It was first discovered on the cell membrane of fibroblast in 
1975; thereafter, it became the most thoroughly studied receptor among all the 
known receptor tyrosine kinases (RTKs).  
 
EGFR belongs to the HER family of RTK, namely HER1/EGFR, HER2/neu, HER3 and 
HER4, all have frequently been found to be overexpressed in epithelial tumours. 
They share the typical RTK molecular architecture, with a ligand-binding 
extracellular domain, a transmembrane helix, juxtamembrane regulatory regions, a 
cytoplasmic tyrosine kinase domain and a carboxy-terminal tail (Inamura, Ninomiya 
et al. 2010). 
 
All receptors of the HER family have a highly conserved intracellular tyrosine kinase 
domain, although HER3 contains substitutions of critical amino acids in this kinase 
domain and therefore lacks of kinase activity; while the extracellular domains are 
less conserved among the four receptors, suggesting that they have different 
specificities in ligand binding. In addition, there are no known growth factors that 
bind to HER2 but HER2 is the preferred dimerisation partner for the other activated 
HER receptors (Normanno, De Luca et al. 2006; Lemmon and Schlessinger 2010).  






The extracellular domain of EGFR is comprised of four domains (I–IV). The 
unliganded monomer is held in closed conformation by an intra-molecular tether 
formed by loops in cysteine-rich domains I and III. The many cysteine residues form 
22 disulfide bonds (Pedersen, Meltorn et al. 2001). When specific ligand binds to 
the cell surface extracellular domain of EGFR, the intra-molecular tether is broken 
and the receptor is opened into an extended conformation which interacts back-to-
back with another monomer (as illustrated in Figure 2). This promotes receptor 
homo- or hetero-dimerisation and phosphorylation on the tyrosine residues in the 
intracellular portion of the receptor (Roskoski 2004; Kumar, Petri et al. 2008). 
Domains I and III of HER2 interact directly with one another and this stabilise the 
Figure 2: Ligand induced conformational changes in the EGFR ectodomain. 
Upon ligand binding, the rotation of domains I/II above the axis of domain II/III 
junction activates tethered EGFR ectodomain into active EGFR dimers. 
 
Modified from Kumar, A., E. T. Petri, et al. (2008) J Clin Oncol 26(10): 1742-1751. 
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extended configuration of HER2 extracellular region. This close proximity of domain 
I and III explains the absence of natural ligands for HER2 (Ferguson 2008).  
 
Ligand-induced EGFR dimerisation is thought to be the key stimulatory step, leading 
to transactivation of downstream kinase targets and initiation of signalling cascades. 
There are eight known EGF agonists: EGF, transforming growth factor α (TGFα), 
amphiregulin (AR), betacellulin (BTC), epigen (EPN), epiregulin (EPR), heparin 
binding EGF-like growth factor (HB-EGF) and neuregulin 2-β (Ferguson 2008; 
Henriksen, Grandal et al. 2013). Furthermore, a 140kDa mutated version of EGFR 
was found in 1988, referred to as EGFRvIII. This mutation lacked the ligand binding 
domain but demonstrated constant activation without any ligand binding, and was 
able to activate downstream signalling cascades. EGFRvIII mutation was found in a 
subset of patients with breast, gliomas, prostate and ovarian tumours (Pedersen, 
Meltorn et al. 2001). 
 
The juxtamembrane region, which is between the membrane and the tyrosine 
kinase domain, plays a role in receptor downregulation and sensitation. Three 
serine/threonine phosphorylation sites are present in this region: Thr654, Thr669 
and Ser671. It was known that Protein kinase C (PKC) phosphorylates Thr-654 and 
inhibits the kinase activity as well as ligand binding to EGFR. Phosphorylation of 
EGFR at Tyr845 in the kinase domain is implicated in stabilizing the activation loop, 
while Lys721 participates in ATP-binding activity (Pedersen, Meltorn et al. 2001). 
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Clinical interest in the EGFR gene has been heightened with the FDA approval of 
specific EGFR tyrosine kinase inhibitors (e.g. Gefitinib). EGFR protein overexpression 
has been reported to occur in 14–91% of breast cancers (see Table 1) and a various 
type of tumours. EGFR gene amplification generally results in increased protein 
expression (Marquez, Wu et al. 2004; Bhargava, Gerald et al. 2005; Shia, Klimstra et 
al. 2005; Dacic, Flanagan et al. 2006). EGFR protein overexpression without gene 
amplification occurred in only 2% in breast carcinomas (Bhargava, Gerald et al. 
2005). The data for the relationship between the presence of EGFR gene 
amplification and responses to EGFR tyrosine kinase inhibitors are still limited. 
Other mechanisms such as gene mutation and transcriptional or post-
transcriptional factors might also have a role in the expression of EGFR protein. 
Table 3: The expression of EGFR in various tumour types. 
EGFR expression has been detected to varying degrees in a wide range of solid cancers. 
Reported values are 14 to 91% for breast carcinomas. 
Inamura, K., H. Ninomiya, et al. (2010) Arch Pathol Lab Med 134(1): 66-72. 
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There are a number of approaches designed to target EGFR. Patients might 
demonstrate benefits from treatment with one of the following agents, either alone, 
or in combination with standard chemotherapy. 
 
Therapeutic antibody against EGFR 
Cetuximab (also known as Erbitux and IMC-C225), is a humanised mouse 
monoclonal antibody that binds to the receptor with higher affinity than EGF or 
TGFα, preventing receptor dimerisation (Roskoski 2004). Although Cetuximab is 
used as monotherapy or in combination with chemotherapeutic agents for some 
patients with colorectal (Cunningham, Humblet et al. 2004; Saltz, Meropol et al. 
2004), head and neck (Baselga, Trigo et al. 2005), and non-small cell lung cancer 
(Fischer, Griesinger et al. 2012), the response rates were modest (Dancey and 
Sausville 2003; Roskoski 2004). 
 
For breast cancer, the clinical response rates vary between clinical studies, ranging 
from 6-49%, in part, depending on the type of breast cancer, the stage of the 
disease, and the treatment used (Modi, D'Andrea et al. 2006; Dickler, Rugo et al. 2008; 
Hudis and Gianni 2011). A recent phase II study by Carey et al. reported a poor response 
(in fewer than 20% of patients) to combination Cetuximab plus Carboplatin among the 
metastatic TNBC patients (Carey, Rugo et al. 2012). Modi et al. reported a withdrawal of a 
phase I trial using the combination of chemotherapeutic agents Paclitaxel and 
Cetuximab, due to the high level of dermatologic toxicity and disappointing efficacy 
(Modi, D'Andrea et al. 2006). 
| - 30 -  
 
  
Small molecule tyrosine kinase inhibitors of EGFR 
Most frequently mutated gene coding for the intracytoplasmic tyrosine kinase 
domain of EGFR occurs from exon 18 to 24. Particularly, 90% of these mutations 
occur with the deletion in codons 746 to 750 of exon 19 (del746_A750) in the 
catalytic site and transversion of T to G in codon 858 of exon 21 (L858R) in the 
activation loop. Both cause conformational change of the tyrosine kinase domain, 
resulting in constant activation of EGFR without ligand binding (Pao and Miller 2005; 
Inamura, Ninomiya et al. 2010).  
 
Two examples of the reversible small molecule for EGFR inhibition are Gefitinib 
(also known as Iressa, or ZD1839) (Baselga 2002; Dancey and Sausville 2003) and 
Erlotinib (also known as Tarceva, or OSI-774) (Baselga and Hammond 2002). Both 
tyrosine kinase inhibitors (TKIs) are advanced in clinical development for a broad 
range of solid tumours. These small molecules competitively inhibit ATP binding to 
EGFR, thereby hindering the receptor autophosphorylation and kinase activation 
(Pedersen, Meltorn et al. 2001). 
 
Corkery et al. have demonstrated the combination of Gefitinib with chemotherapy 
enhanced cell cycle arrest in basal-like breast cancer cell-lines, with reduced 
phosphorylation of ERK and Akt protein kinases (Corkery, Crown et al. 2009). 
Gefitinib has also been shown to induce inactive unphosphorylated EGFR/HER2 
heterodimers resulting in anti-proliferative effect in EGFR and HER2 expressing 
breast cancer cell-lines (Anido, Matar et al. 2003).  
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Gefitinib has been used in clinical trials for EGFR-expressing cancers, such as head 
and neck and non–small-cell lung cancer (NSCLC) (Cappuzzo, Gregorc et al. 2003; 
Cohen, Rosen et al. 2003; Fukuoka, Yano et al. 2003). Mok et al. have demonstrated 
the use of Gefitinib for the treatment of pulmonary adenocarcinoma was 
significantly more effective in patients harbouring EGFR mutation that those that 
were negative for the mutation (Mok, Wu et al. 2009).  
 
It has been reported that mutations in the tyrosine kinase domain of EGFR were 
associated with Gefitinib sensitivity in patients with NSCLC and the tumours were 
highly responsive to EGFR tyrosine kinase inhibitors (Lynch, Bell et al. 2004; Paez, 
Janne et al. 2004; Inoue, Kobayashi et al. 2009; Sugio, Uramoto et al. 2009). Such 
mutations were also associated with sensitivity of Erlotinib, with over 80% of 
patients marked clinical improvement on Gefitinib or Erlotinib have been shown to 
contain mutations in the exons encoding the EGFR tyrosine kinase domain (Pao, 
Miller et al. 2004; Pao and Miller 2005). 
 
Gefitinib has been used in combination with Trastuzumab as a potential 
combination for treating Trastuzumab-resistant HER2 positive metastatic breast 
cancer (Somlo, Martel et al. 2012). Gefitinib has demonstrated a median duration 
of clinical benefit of 10.9 months (Dennison, Jacobs et al. 2007). Erlotinib has been 
used in a number of clinical studies for EGFR-expressing cancers (Perez-Soler, 
Chachoua et al. 2004; Dickler, Rugo et al. 2008; Britten, Finn et al. 2009), but also 
demonstrated limited clinical benefits. It was shown that patients with positive 
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EGFR expression have a higher response rate (11.3%) compared to patients with 
negative EGFR expression (3.8%), with overall survival rate of 6 months (Shepherd, 




Other antibody entities against EGFR were investigated for anti-tumour activity, 
such as Panitumumab (ABX-EGF) (Yang, Jia et al. 2001; Peeters, Price et al. 2010) or 
bispecific antibody MDX-447 which targets EGFR as well as the high affinity Fc 
receptor (FcγRI) and enhances immune-based killing by antibody-dependent 
cellular cytotoxicity (ADCC) (Pedersen, Meltorn et al. 2001; Fury, Lipton et al. 2008). 
Alternative tyrosine kinase inhibitors (both reversible and irreversible inhibitors) are 
in preclinical or early clinical development, which have different specificities for 
HER family members (Baselga and Hammond 2002). 
 
Casamassimi et al. reported a gene therapy strategy using antisense 
oligonucleotides to decrease EGFR ligands and EGFR expression in vitro, and 
therefore inhibit the proliferation of tumour cells (Casamassimi, De Luca et al. 
2000). The antisense oligonucleotides targets cells by hybridising to complimentary 
messenger RNA (mRNA) sequences, preventing of the translation of the mRNA and 
inhibit gene expression (Wagner 1994). 
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In summary, despite strong preclinical data, only a subset of cancer patients shows 
clinical response to these therapies. In addition, patients who demonstrated initial 
response can become refractory to continuous treatment. However, it is likely that 
the true prognostic significance of the EGFR has been underestimated as the 
published studies only assessed total cellular EGFR levels, rather than the activated 
form of the receptor, and were not standardised with regard to patient selection or 
assay methods.  
 
This lack of clinical efficacy of EGFR-targeted treatments indicated the use of a 
compensatory mechanism by cancer cells for bypassing the therapeutic effect of 
EGFR-specific agents. The inadequate inhibition of EGFR pathway and its 
downstream signalling components or alternate signalling escape routes, such as 
HER2/3/4, c-Met and fibroblast growth factor receptor (FGFR) (Sharpe, Pearson et 
al. 2011), might also contribute to the resistance to the therapeutic treatments.  
 
In order to select the most beneficial treatments and combinatorial strategies, it is 
important to obtain a better understanding of what molecular factors, or 
biomarkers, which may influence the therapeutic sensitivity of the EGFR network 
and their roles in cancer development. 
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1.5 EGFR and signalling proteins 
 
Ligand binding to EGFR on the cell surface induced EGFR auto-dimerisation and 
cross-interaction with other HER partners. A transient signalling complex composed 
of adaptor and effector proteins was then assembled. The dissociation of this 
complex led to a cascade of signalling events, followed by gene activation and 
cellular response. 
 
Tyrosine kinases are enzymes that transfer the ϒ phosphate of ATP to specific 
tyrosine residues (Baselga and Hammond 2002). There are several tyrosine 
phosphorylation sites that are phosphorylated upon ligand binding: Tyr992, 
Tyr1068, Tyr1086, Tyr1148 and Tyr1173, which serve as binding sites for signalling 
molecules to transmit signals for the phosphorylation and activation of downstream 
targets (as illustrated in Figure 2) (Roskoski 2004). After auto-phosphorylation or 
trans-phosphorylation by other kinases such as Src and Jak-2, the intracellular 
tyrosine residues of EGFR can serve as docking sites for various transducers and 
adaptor proteins that contain Src-homology-2 (SH2) or phospho-tyrosine-binding 
(PTB) domains. Signalling molecules that associate directly with EGFR included 
adaptor proteins Grb-2, Nck, Shc, Crk and Dok-R, as well as phosphatases PTB-1B 
and SHP-1, and tyrosine kinase Abl; while Cbl, Pl3K-C2b and Stat5b are thought to 
have an indirect association with EGFR (Olayioye, Neve et al. 2000; Jorissen, Walker 
et al. 2003). 
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Downstream targets often include serine/threonine kinases such as the mitogen-
activated protein kinase (Ras/Raf/MAPK) protein kinase cascade, which is recruited 
via Grb-2 and Son-of-sevenless (Sos), and involved in cell proliferation; the 
phosphatidylinositol-3-kinase (Pl3K)-activated Akt pathway, which induces cell 
motility and invasion; and the Janus kinase (JAK)-dependent signal transducers and 
activator of transcription (STAT) pathway which enhances cell migration (see Figure 
3) (Jorissen, Walker et al. 2003; Andl, Mizushima et al. 2004). 
 
Genetic dysregulation in any of the individual molecules involved in EGFR signalling 
might promote development of cancers. For example, KRas is a small G protein that 
acts as a transducer linking ligand-dependent receptor activation to downstream of 
EGFR. The gain-of-function mutations in KRas codons 12 and 13 can lead to 
constitutive signalling and activation of MAPK- and PI3K-dependent pathways 
(Bardelli and Siena 2010). It has been showed that patients with mutant KRAS 
codon 12 or 13 in metastatic colorectal cancer were unlikely to benefit from EGFR-
targeted therapy (Van Cutsem, Kohne et al. 2009; Peeters, Douillard et al. 2013). 
However the effects of somatic mutations are often manifested through the 
complexity of the interaction between proteins expressed by aberrant genes; the 
aberrant function at a protein level must therefore be assessed even in the 
presence of these genetic changes. Protein complex formation, conformational 
change and post-translational modifications such as receptor phosphorylation can 
also alter the functional outputs of the cell (e.g. migration and proliferation) (Citri 
and Yarden 2006).   








Figure 4: Schematic illustration of the EGFR and downstream signalling pathways. 
There is a rich cross-talk among the HER family. In the input layer, specific ligand such as 
EGF binds to EGFR leading to receptor dimerisation (homo- or hetero-dimers with other 
HER receptor members). Binding of ligand to the EGFR ectodomain triggers the 
interaction with a number of protein kinases such as adaptor protein (Shc, Grb2 and Crk), 
Ras-specific GTPase-activating protein (GAP), PI3K, second-messenger-generating 
enzyme PLCγ, and ubiquitin ligase (Cbl). Activation of these protein kinases initiates 
signalling cascades and translates in the nucleus into distinct transcriptional programmes 
in regulation of a host of cellular function, including cell growth, migration and survival. 
 
Modified from Roskoski, R., Jr. (2004) Biochem Biophys Res Commun 319(1): 1-11 
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1.6 Negative regulatory mechanisms for EGFR signalling 
 
A transient signalling complex composed of adaptor proteins and effectors is 
assembled following the activation of EGFR. For the regulation of signal output, this 
process is carefully coordinated by negative regulatory mechanisms by promoting 
receptor internalization, intracellular trafficking, and subsequent ubiquitination and 
degradation of both ligand and receptor molecules (Henriksen, Grandal et al. 2013).  
 
During signal termination, activated receptor-ligand complexes are endocytosed in 
clathrin-coated pits and ubiquitin ligase Casitas B-lymphoma (Cbl) is recruited to 
target the receptors for ubiquitination (Marmor and Yarden 2004). Early 
endosomes merge and mature to form multivesicular bodies (MVB) and late 
endosomes.  
 
Two distinct processes have been identified to determine the fate of the 
internalised receptors (Sorkin and Goh 2009) (see Figure 4). First process involves 
the continuous association with Cbl, which interacts with Tyr1045 on EGFR and 
targets the receptors to the lysosomal compartment and catalyzes ubiquitination 
and intracellular degradation. The second process occurs with the uncoupling of Cbl 
in early endosome; EGFR may remain associated with EGF in the early endosomes 
and retain the capacity to continue signalling, or it may release the EGF into the 
acidic environment and the ligand will get degraded by the accumulated hydrolytic 
enzymes. Receptors are instead recycled to the plasma membrane (Lenferink, 
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Pinkas-Kramarski et al. 1998; Marmor and Yarden 2004). It has been shown that 
endocytosis of the receptor is required for pro-angiogenic vascular endothelial 
growth factor receptor (VEGFR) to activate ERK1/2 in endothelial cells (Gourlaouen, 
Welti et al. 2013).  
 
EGFR activity can also be downregulated by tyrosine specific phosphatases, such as 
density-enhanced phosphatase-1 (DEP1), which dephosphorylates EGFR and 
decreases the signal outputs (Yarden 2001; Dikic and Giordano 2003; Bublil, Pines 
et al. 2010; Lemmon and Schlessinger 2010; Avraham and Yarden 2011). Other 
EGFR phosphatases include PTP1B (Haj, Verveer et al. 2002; Reynolds, Tischer et al. 
2003) and the protein tyrosine phosphatase TCPTP (Mattila, Pellinen et al. 2005). 
 
  






Figure 5: HER family receptor internalisation and intracellular trafficking. 
Ligand binding induced phosphorylation of EGFR and recruitment of Cbl, which 
targets the receptors for ubiquitination. Receptors are then sorted into clathrin-
coated pits by a multiprotein complex that includes coat adaptors such as Epsin and 
Eps15. Fission of clathrin-coated vesicles is mediated by GTPase dynamin. Ligand is 
released when the internal pH of early endosomes decreases. With the 
accumulation of hydrolytic enzymes that degrade the ligands, receptors are allowed 
to travel back to the surface. Trafficking from early to late endosomes/MVB is 
dependent on its continued association with Cbl. MVB sorting is regulated through 
recognition of ubiquitylated cargo by Hgs/Vps27p, Tsg101/Vps23p and other 
components of ESCRT complexes. Fusion of the MVB with the lysosome results in 
degradation of the contents of the internal vesicles. 
 
Modified from Marmor, M. D. and Y. Yarden (2004) 23(11): 2057-2070 
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1.7 c-MET tyrosine kinase receptor 
 
In recent years, oncology therapeutics development has started to pay more 
attentions on the role of c-MET and its relationship with EGFR. (Karamouzis, 
Konstantinopoulos et al. 2009) 
 
Similar to EGFR, c-MET is also a proto-oncogene tyrosine kinase receptor, which 
drives the malignant progression of several types of cancer such as colorectal 
cancer, head and neck squamous cell cancer (Knowles, Stabile et al. 2009; Liska, 
Chen et al. 2011) and HER2 overexpressing breast cancer (Shattuck, Miller et al. 
2008), whereas the c-MET signalling pathway activity was up-regulated after 
targeted inhibition of the HER family of tyrosine kinase receptor. 
 
In tumour, several cytokines such as TGFβ induce transcriptional upregulation of 
both c-MET and its ligand hepatocyte growth factor (HGF). Besides transcriptional 
control, the levels of c-MET expression at the cell surface can also be finely 
regulated by proteolytic cleavage and ubiquitin-mediated degradation. Functionally, 
a direct shedding of the c-Met ectodomain from tumour cells following proteolytic 
cleavage may provide an alternate mechanism for producing circulating c-Met and 
was shown to be an indicator of malignant potential and overall tumour burden 
(Athauda, Giubellino et al. 2006). 
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Constitutive activation of c-MET is depended on two mechanisms: ligand-
dependent activation due to elevated level of HGF, or ligand-independent 
activation due to gain-of-function mutation of c-MET, overexpression and loss of 
negative regulators, which promotes c-MET dimerisation and auto-phosphorylation 
on tyrosine residues Tyr1234 and Tyr1235 at the catalytic kinase domain. This leads 
to further phosphorylation on the docking tyrosines for the recruitment of 
scaffolding transducer and adaptor proteins, leading to activation of downstream 
oncogenic effectors such as ERK protein kinase and PI3K lipid kinase. In addition, 
phosphorylation of Tyr1003 promotes internalization and degradation of c-MET 
through Cbl interaction (Trusolino, Bertotti et al. 2010). 
 
The major c-MET-regulated pathways are very similar to those of the EGFR network 
which control cell cycle progression, cell growth and survival. It has been suggested 
potential crosstalk between c-MET with EGFR, although it is not fully understood 
how they mediate each other (Guo, Villen et al. 2008). c-MET may render cancer 
cells resistant to EGFR-targeted therapies, possibly via its hetero-dimerisation with 
EGFR or by re-stimulating important signalling pathways (Mueller, Hunter et al. 
2008; Mueller, Yang et al. 2010; Dulak, Gubish et al. 2011; Liska, Chen et al. 2011). 
 
Clinical benefit of targeting the c-Met receptor has been reported in many types of 
human solid tumours, including non-small-cell lung cancer (NSCLC), breast, prostate, 
liver and renal cancers, for which the degree of c-Met expression correlates with 
poor patient prognosis (Nakajima, Sawada et al. 1999; Gherardi, Birchmeier et al. 
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2012). Notably in patients with NSCLC, combining EGFR (Erlotinib) and c-MET 
(MetMAb) inhibitors increased progression-free survival in patients with high levels 
of c-MET expression compared with the group receiving Erlotinib alone (Gherardi, 
Birchmeier et al. 2012). Preclinically, similar synergy has been seen between 
Foretinib (c-MET TKI) and Lapatinib (EGFR-HER2 dual TKI) (Liu, Shi et al. 2011). 
Either targeting alone or in combination with an anti-EGFR therapeutic, c-MET is 
undoubtedly a valuable target for cancer therapy.  
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1.8 Molecular imaging: FRET-FLIM technology 
 
The interactions between the vast number of membrane receptors and secondary 
messenger molecules are the keys to determine cell behaviour. Methods of cancer 
prognosis estimation rely on clinical data, anatomical staging and histopathological 
features based on existing markers. Molecular fluorescence imaging of the spatial-
temporal expression/interaction of protein complexes in situ allows us to obtain 
better understanding of the cancer proteome that might translate to potential 
clinical benefits. 
 
Fluorescence is a result of a three-stage process. Each electronic energy state has 
several energy levels as represented by the closely packed horizontal lines shown in 
Figure 5. The resting state of a fluorophore is in the lowest level of energy, ground 
state (S0). Photon energy, supplied by an external source, such as a laser, can be 
absorbed by the fluorophore, creating an excited electronic singlet state (S1). The 
excited state exists for a finite time followed by relaxation into the lowest level of 
the excited singlet state. The average length of time spent in the higher electronic 
state is termed as fluorescence lifetime (tau or τ). 
 
Energy is then dissipated either via radiative or non-radiative processes. Radiative 
transfer results in the fluorescent emission and the excited molecule will return to 
the ground state; whilst Förster (or fluorescence) resonance energy transfer (FRET) 
is a non-radiative, dipole-dipole coupling process where energy from a donor 
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fluorophore molecule is transferred to an acceptor fluorophore that are presented 
in close proximity (less than 10 nm). The first step of a FRET process is the 
absorption of photon energy by the donor molecule, which is then excited from 
ground state to the excited electronic singlet state. When the excited donor is in 
close proximity with an acceptor fluorophore, the energy is transferred from the 
excited donor to the acceptor, which generate an excited acceptor that in turn 
release the energy by emitting photon and returning to its ground state. 
 
FRET efficiency is inversely proportional to the sixth power of the molecular 
distance between donor and acceptor and the fluorescence life-time of the 




Where R0 is the Förster radius (at which 50% of the excitation energy is transferred 
to the acceptor); r is the separation between the fluorophores; τ fret is the lifetime 
of the interacting fraction and τ d is the lifetime of the donor in the absence of 
acceptor. FRET can only be observed when the two fluorophores are within 








Figure 6: Jablonski representation of FRET 
FRET is the process of energy transfer from an excited donor fluorophore to an 
acceptor fluorophore in close proximity. (Left) The donor fluorophore, GFP, is excited 
in isolation. (Right) When donor and acceptor (GFP and RFP) are in close proximity, 
energy is transferred from the excited donor fluorophore to the acceptor, generating 
an excited acceptor that in turn can emit fluorescence by reverting to its ground 
state. 
 
Modified from Kelleher, M. T., G. Fruhwirth, et al. (2009) Target Oncol 4(3): 235-252. 
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A few methods have been established to detect FRET, for example acceptor 
photobleaching, fluorescence polarization imaging and fluorescence lifetime 
imaging microscopy (FLIM) (Beutler, Makrogianneli et al. 2008). FLIM is a state-of-
the-art technique that provides a high resolution and sensitive readout of the 
fluorescence signals, which avoids potential artefacts, such as the destructive of 
fluorophore signal and low signal-to-noise ratio that can be inherent using other 
FRET measurement techniques (Peter and Ameer-Beg 2004). FRET-FLIM studies 
have received increased attention in recent years driven by the availability of FRET-
based molecular probes, advanced quantitative analysis methodologies and the 
increasingly sophisticated microscopy and computer systems (Festy, Ameer-Beg et 
al. 2007). 
 
The two principal ways to measure fluorescence lifetime are frequency domain and 
time domain-based methods. This project measured fluorescence lifetime by using 
time-correlated single-photon counting (TCSPC) method, where an optical pulse of 
light from the laser source is used to excite the donor fluorophore (Beutler, 
Makrogianneli et al. 2008). The decay of the intensity of fluorescence signal is then 
measured as a function of time (see Figure 6 for an illustration of the system set 
up). Once the FLIM data acquisition has been completed, the fluorescence lifetime 
is then calculated by fitting exponential fluorescence decay models to the 
measured intensities. The main advantage of using donor FLIM is that this method 
is independent of fluorophore concentration and donor-acceptor stoichiometry. It 
also does not require corrections for donor emission crosstalk in the acceptor 
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channel, direct acceptor excitation at the donor excitation wavelength, nor 
knowledge of detection-correction (which involves quantum yields, donor and 
acceptor detection efficiencies and varies with conditions such as pH and optical 
alignments) (Bastiaens and Squire 1999; Wouters, Verveer et al. 2001; Festy, 
Ameer-Beg et al. 2007).  
 
The development of TCSPC FLIM combined with two-photon microscopical 
techniques has proven to be a powerful technology to study three-dimensionally 
sectioned cellular data. These advantages result from the use of intense near-
infrared light to induce non-linear absorption in the probe fluorophore, whereby 
photobleaching and photodamage are greatly reduced. The intensity dependence 
of the non-linear absorption confines the excitation to a small volume in focal plane 
of the imaging lens and allows very high spatial (angstrom) and temporal 
(nanosecond) resolution for studying molecular interactions between two proteins. 
These techniques are used to study the functional and structural aspects of 
inter/intra-molecular mechanisms such as protein-protein interaction, 
conformational change and in applications such as high-throughput screening 










Figure 7: A schematic of a TCSPC FLIM set up. 
A pulsed laser (black arrows) excites the sample at a MHz repetition rate, and the 
fluorescence (grey arrows) is detected with a photomultiplier detection system. 
The electronic signals for the detected photons and for the beam scan 
synchronisation (…) are fed into a TCSPC card in a PC. The time delay between the 
laser excitation pulse and the arrival of the fluorescence photon is measured many 
times, and a histogram of photon arrival times is built up in each pixel, which 
represents the fluorescence decay in each pixel. Subsequent data analysis allows 
the extraction of fluorescence lifetime from the decays, and its visualisation in a 
FLIM map. 
 
Modified from Festy, F., S. M. Ameer-Beg, et al. (2007) Mol Biosyst 3(6): 381-391. 
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1.9 CrkII-based probe for monitoring EGFR activity in cells 
 
 PHOGEMON Project  
In 2001, Phosphorylation and Guanine-nucleotide Exchange Monitoring Project 
(PHOGEMON Project) was established in Miki Matsuda’s laboratory in Kyoto 
University, aimed to develop monitors for kinases and G proteins, the two key 
players of the signal transduction, using molecular fluorescence imaging. 
(http://www.lif.kyoto-u.ac.jp/labs/fret/e-phogemon/phomane.htm) 
 
Integrated biosensors have been developed in based on intra-molecular FRET 
where the FRET donor and acceptor are fused in the opposing ends of the same 
protein molecule, avoiding the complication of variable stoichiometry between 
inter-molecular FRET pairs. FRET-based biosensor can be used to visualize 
spatiotemporal changes of protein activity as a consequence of stimulation or drug 
treatment in live/fixed cells, tissues or the deep tissue measurement in pre-clinical 
tumour models (Festy, Ameer-Beg et al. 2007).  
 
eGFP/mRFP1 biosensor pair 
CFP/YFP pair has been widely used in ratiometric FRET experiments (Kurokawa, 
Mochizuki et al. 2001; Yoshizaki, Ohba et al. 2003; Yoshizaki, Aoki et al. 2006; Aoki, 
Kiyokawa et al. 2008; Nishioka, Frohman et al. 2010; Kunida, Matsuda et al. 2012), 
but it carries a number of disadvantages such as substantial emission cross-talk due 
to spectral overlap (see Figure 7) and CFP alone may exhibit bi-exponential decay 
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kinetics, making quantitative analysis of an interacting FRET population difficult 
(Peter, Ameer-Beg et al. 2005). 
 
The introduction of enhanced GFP (eGFP) and the monomeric variant of DsRed 
(mRFP1) provided a better suitable pair for donor FRET-FLIM assays, whereas 
mRFP1 has lower aggregation problems to form oligomers and has little or no green 
component in its fluorescence emission (Fruhwirth, Fernandes et al. 2011). This 
solved the problem of emission cross-talk, since eGFP can be excited at a 
wavelength beyond the excitation spectrum of mRFP1 (see Figure 7). In addition, 
eGFP is a photostable fluorophore that displays mono-exponential fluorescence 
decay, offering multiple advantages over the currently available CFP/YFP pairs 
(Peter, Ameer-Beg et al. 2005).  









Figure 8: Emission spectra for CFP/YFP and eGFP/mRFP1 fluorophore pairs. 
A large area of spectral overlap of cyan (CFP)/yellow (YFP) fluorescent protein 
pair was shown in the upper panel; compared to the low level of emission cross-
talk of the enhanced green (eGFP)/monomeric red (mRFP1) pair in the lower 
panel. Spectra were created using online software Fluorescence SpectraViewer 
from Invitrogen. 
 








CrkII belongs to a family of adaptor proteins with Src-homology 2 (SH2) domain 
which contains a phospho-tyrosine binding site, and Src-homology 3 (SH3) domains 
connected with flexible peptide linkers that transmits signals from tyrosine kinases. 
Alternative splicing of the Crk transcript yields two different products, CrkI (SH2-
SH3) and CrkII (SH2-SH3-SH3) (Figure 8) (Kobashigawa, Sakai et al. 2007). 
 
The primary function of CrkII is to recruit phosphotyrosine-containing proteins (e.g. 
adaptor proteins paxillin and p130cas) and growth factor receptors (e.g. EGFR), 
through SH2/p-Tyr221 interaction. The output from CrkII depends on the SH3-
binding proteins, which recruit cytoplasmic enzymes such as C3G (guanine 
nucleotide exchange factor (GEF) for Rap 1), Sos (GEF for Ras), protein tyrosine 
phosphatase 1B (PTP1B) and c-Abl cytoplasmic tyrosine kinase in response to 
tyrosine kinase activation (Takino, Tamura et al. 2003). Only amino acids 1–236 
Figure 9: Domain structure of Crk proteins. 
Adaptor protein Crk consists of SH2 and SH3 domain. CrkI contains a single SH3 
domain while CrkII contains two. Phosphorylation site locates on Tyr221. The 
construction of Picchu-X sensor (amino acid 1-236) does not affect the 
phosphorylation of the protein. 
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were used in the construction of Picchu-X sensor. As part of the c-terminal SH3 was 
lacking, the output signals were reduced with the low affinity to target proteins 
(Kobashigawa, Sakai et al. 2007); however, the phosphorylation site Tyr221 
remained for activity sensing. 
 
Picchu, stands for ‘Phosphorylation Indicator of Crk Chimeric Unit’, is an example of 
eGFP/mRFP1 biosensor that has been extensively studied in this project. The use of 
this probe for reporting EGFR kinase activities in cells have been reported 
previously (Kurokawa, Mochizuki et al. 2001; Itoh, Kurokawa et al. 2005; Aoki, 
Kiyokawa et al. 2008). A flaw of the Picchu probe is that the diffusion of the probe is 
too fast to delineate the sub-cellular localization of tyrosine kinase activity. To 
overcome this flaw, Picchu was subcloned with carboxy-terminal CAAX tail of k-Ras 
as a plasma membrane-anchoring motif, generating the Picchu-X biosensor 
(Kurokawa, Mochizuki et al. 2001).  
 
Picchu-X consists of YFP, spacer (Leu-Asp), CrkII protein (amino acids 1–236), spacer 
(Gly-Arg), CFP, spacer (Gly-Arg-Ser-Arg), and CAAX tail of K-Ras (amino acids 169–
188). The new Picchu-X sensor was modified by the excision of the sensor module 
between YFP and CFP and insertion between the mRFP1 and eGFP. The resultant 
eGFP- and mRFP1-tagged Picchu-X constructs retain the original design of the CFP-
YFP tagged version (Itoh, Kurokawa et al. 2005). Phosphorylation of CrkII protein 
occurs after activation of EGFR; hence FRET measurement of Picchu-X provides a 
sensitive means for monitoring EGFR activity. 




Upon activation of tyrosine kinases, CrkII undergoes a change in intra-molecular 
folding, which promotes binding of SH2 domain to phosphorylated Tyr221 and 
brings eGFP in close proximity to mRFP1, thereby triggering fluorescence energy 
transfer (as illustrated in Figure 9) (Kurokawa, Mochizuki et al. 2001; Itoh, 
Kurokawa et al. 2005; Aoki, Kiyokawa et al. 2008).  











Figure 10: Schematic representation of Picchu-X. 
Picchu, stands for ‘Phosphorylation Indicator of Crk Chimeric Unit’, is designed to 
monitor activity of the CrkII protein. Membrane anchoring domain, CAAX, is 
expressed at the C-terminal end generating the Picchu-X sensor. Upon stimulation of 
EGFR, binding of SH2 domain to phosphorylated Tyr221 brings eGFP in close 
proximity to mRFP1, thereby triggering fluorescence energy transfer. 
 
Modified from Itoh, R. E., K. Kurokawa, et al. (2005) Exp Cell Res 307(1): 142-152. 
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1.10 Optical imaging for network screen 
 
Constructing a protein interaction network map 
The current trend in optical proteomic imaging of fluorescent protein in situ 
provides an excellent tool to understand the detailed molecular mechanism in 
various stages of cancer progression with better preservation of post-translational 
protein modifications or protein-protein interactions, especially on the sensitivity of 
detecting membrane events compared to biochemical extraction of membrane 
complexes. It is also useful to validate the treatment strategy for individuals with 
high risk of metastasis and disease relapse by correlating their profiles with 
multivariate proteomic signatures and using high content drug screens, thus sparing 
unnecessary and potentially toxic treatments (Kelleher, Fruhwirth et al. 2009). The 
availability of vast amount of clinical and biological literature databases, together 
with the technological and bioinformatics advancements in the past decades, 
protein activity sensing/imaging technique allow us  to interrogate large-scale of 
protein network in order to obtain a better understanding of what molecular 
factors may influence the therapeutic sensitivity.  
 
Data reported from a variety of experiments (e.g. yeast two-hybrid assays, mass 
spectrometry, immunohistochemistry, Western blot, coimmunoprecipitation, 
fluorescence microscopy, proteins chips, microarrays, ChIP-Seq, RNA-Seq) currently 
available from public datasets can be integrated and mapped into protein-protein 
interaction networks (interactomes) (Cusick, Yu et al. 2009; Fruhwirth, Fernandes et 
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al. 2011). These datasets are routinely updated based on collection of new 
functional and genomic information, to generate comprehensive and up-to-date 
resource for studying the human proteome. 
 
Human Protein Reference Database 
Human Protein Reference Database (HPRD) is a resource of curated proteomic 
information including protein-protein interactions, post-translational modifications 
and tissue expression (Keshava Prasad, Goel et al. 2009). 
(http://www.hprd.org) 
 
 To date, this database has documented 8958 protein-protein interactions based on 
yeast two-hybrid analysis alone, 8827 interactions were based on in vitro and 7163 
on in vivo experiments. Detection of 2410 interactions was confirmed by all three 
methods. In this project, HPRD was used to identify sets of ‘’seed proteins’’, specific 
to metastatic phenotype, and generate interconnected network/subnetwork maps 
based on first order (direct partners) and second order (partners of partners) from 
seed proteins (Fruhwirth, Fernandes et al. 2011). 
 
  




Comprehensive map would be an invaluable asset for the understanding of 
biological processes and molecular mechanisms at the systems biology level. Such 
biomolecular interaction networks can be visualised using online software, 
Cytoscape, as a tool to filter and interpret selection of relevant subnetworks.  
 
Each protein in the network is annotated as a node and its interactions with other 
proteins as edges. Another key feature of Cytoscape is its ability to set visual 
aspects of nodes and edges, such as shape, colour and size, based on attribute 
values. This data-to-visual attribute mapping allows multiple types of data to be 
visualised in a single network context (Shannon, Markiel et al. 2003; Cline, Smoot et 
al. 2007). Following this procedure, a subnetwork associated to EGFR was 
constructed and can be used to propose new experiments to interrogate the EGFR-
centric subnetwork of proteins (see Figure 10) (Fruhwirth, Fernandes et al. 2011). 
  







Figure 11: Signalling Network centred EGFR. 
Large-scale map of protein-protein interactions (interactomes) was designed using 
the Human Protein Reference Database. An EGFR-centric subnetwork of proteins 
based on first and second order of interaction partners from the seed proteins (red 
triangles) was generated and visualised using the Cytoscape software.  
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Large-scale high content/high throughput screen 
Many researches are now utilising compound libraries for drug screenings or 
genomic libraries for cellular studies, for which each compound/gene can 
potentially contribute to the cellular function or disease model. The developments 
in instrumentation and image analysis have made microscopy applicable to 
automated high content/high-throughput screening. High content screening (HCS) 
defined as multiparametric approaches for the simultaneous readout of 
spatiotemporally resolved context upon application of small molecule drug 
compounds or small interfering RNAs (siRNAs) at the single-cell level based on 
fluorescence imaging. In recent years, the term HCS is also applied to cell-based 
analysis techniques such as flow cytometry and other label-free assays (Gasparri 
2009; Liang, Chang et al. 2012).  
 
High throughput screening (HTS) can be defined as the automation of experiments 
such that large scale repetition becomes feasible, based on robotic microscopy for 
robust fluorescence intensity readout in combination with high-speed computing 
systems for quantitative analysis and storage of the data (Gonzalez and Negulescu 
1998). Automation is a key to extract multiple parameter information from cells in 
order to improve productivity and to minimise measurement time, while decreasing 
the volumes of reagents required for the assays and maintaining the same 
experimental conditions when examining large number of samples.  
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HC/HTS approaches are increasingly being exploited in modern drug discovery 
(Giuliano, Chen et al. 2004), or use to study cellular mechanisms with imaging-
based siRNA screen (Krausz 2007; Krausz and Korn 2008; Hutchins, Toyoda et al. 
2010; Neumann, Walter et al. 2010). A few automated FRET approaches have been 
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1.11 RNA interference 
RNA interference (RNAi) is a natural process of post-transcriptional silencing of 
individual gene, regulated by either microRNA (miRNA) or small interfering RNA 
(siRNA) that is homologous to the targeted messenger RNA (mRNA). RNAi has an 
important role in innate immune response against foreign long double-stranded 
RNA (dsRNA) from viruses or bacteria (Hannon and Rossi 2004). The enzyme dsRNA-
dependent protein kinase R (PKR) is activated on binding to dsRNA and triggers 
sequence-independent destruction of RNAs. RNAi is also important in directing 
development as well as controlling gene expression (Hannon 2002). 
 
siRNA is a 21-23 nucleotides dsRNA molecule that mediate RNAi mechanism of 
gene suppression. Ribonuclease-III (RNase-III) family enzyme, Dicer, cleaves up long 
dsRNAs in an ATP-dependent manner and delivers these small pieces of siRNA to a 
protein complex called RNA-induced silencing complex (RISC). Each siRNA is 
unwound into two single-stranded RNAs, namely the passenger strand and the 
guide strand. The passenger strand is targeted for degradation, while RISC uses the 
antisense guide strand of the siRNA to identify and degrade the complementary 
mRNAs, resulting in gene silencing and decrease in protein expression (Hannon and 
Rossi 2004; Morris 2005). Similar to siRNA, miRNA of approximately 21 nucleotides 
has also been identified to interfere with gene expression. However, the transcripts 
captured by miRNA-incorporated RISC complex are directed into a ribosome-free 
compartment, named P-body, resulting in translational repression (see Figure 11) 
(Yeung, Bennasser et al. 2005; Kim and Rossi 2007). 











Figure 12: A model of RNA interference mechanism of the miRNA and siRNA 
pathways. 
miRNAs are derived from pro-miRNAs transcribed by RNA Pol II in the nucleus. 
After cropping by Microprocessor, the primiRNAs are processed into pre-
miRNAs and exported into cytoplasm. Both pre-miRNAs and dsRNA/short 
hairpins are trimmed by Dicer to generate miRNA and siRNA duplexes, 
respectively. The guide strand of the duplexes is incorporated into RISC for RNA 
silencing and the passenger strand is targeted for degradation. mRNAs with 
perfect complementary to the siRNAs are targeted to degradation, while 
transcripts captured by miRNA-incorporated complex are directed into the P-
body resulting in translational repression.   
 
Modified from Yeung, M. L., Y. Bennasser, et al. (2005) Cell Res 15(11-12): 935-946. 
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RNAi has now been adopted as a standard methodology for the silencing of gene 
expression in mammalian cells. The use of chemically synthesised RNA duplexes, 
consisting of two 21-nucleotides annealed together to form siRNAs, can be 
introduced into cultured cell to produce effective gene knockdown for the studies 
of protein functions. Synthetic siRNAs can induce RNAi by circumventing natural 
defence mechanism against long dsRNA (>30 nucleotides), bypass the dicing step 
and incorporate into RISC to facilitate the breakdown of homologous mRNA 
sequences (Elbashir, Harborth et al. 2001). However, the use of synthetic siRNAs 
are unable to produce stable gene knockdowns, whereas cells that are transfected 
with siRNAs typically recover from mRNA suppression within seven days or ten 
rounds of cell division.  
 
Other strategy to interference gene expression is using short hairpin RNAs (shRNAs), 
which are expressed from vectors such as plasmids, retroviruses or adenoviruses. 
The main advantage of these vector constructs is that they can be stably 
transfected and amenable to long term studies. Promoter region in the vectors can 
ensure hairpin oligonucleotides are constantly expressed and maintain long-term 
mRNA inhibition (Hannon and Rossi 2004).  
 
RNAi has revolutionised the study of functional definitions for every gene, and is 
being explored as a therapeutic tool (Dorsett and Tuschl 2004; Hannon and Rossi 
2004). Landen et al. reported tumour growth in vivo was suppressed (with up to 
91% reduction in tumour size when combining chemotherapy agent Paclitaxel) after 
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systemic delivery of siRNA-containing liposomal nanoparticles, which contained 
siRNAs targeting the overexpressed tyrosine kinase receptor EphA2 gene in ovarian 
cancer cell lines (Landen, Chavez-Reyes et al. 2005). RNAi has also been used to 
specifically target and prevent viral infections by human immunodeficiency virus 
type-1 (HIV-1) and Hepatitis  virus (Yeung, Bennasser et al. 2005). 
 
 
In this project, a library of siRNA targeting 533 genes encoding for proteins that 
interact with HER1-4 as seed proteins directly or indirectly, was chosen from the 
HPRD. This genome library was purchased from Ambion; three different siRNA 
sequences were available to uniquely silence each of these 533 genes. Combining 
with our in-house semi-automated FRET-FLIM-based HC/HTS imaging technology, 
this library allows us to interrogate the EGFR-centric subnetwork of proteins using 
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1.12 Delivery system – liposomal techniques 
 
The other goal for this project was aimed to develop a synthetic nanoparticle 
delivery system to formulate serum-stable liposomes for in vivo delivery of the 
FRET-based probe to study the dynamics of EGFR activity and its modulation by 
known EGFR kinase inhibitors. This combination of therapeutics and diagnostics is 
referred as theragnostics (Lammers, Kiessling et al. 2010). 
 
 Several liposomal drug formulations have been approved for clinical applications, 
such as PEGylated liposomal Doxorubicin and Paclitaxel, for the treatment of solid 
tumours in patients with breast carcinoma metastases (Noble, Kirpotin et al. 2004; 
Yezhelyev, Gao et al. 2006) and refractory ovarian cancer (Gordon, Fleagle et al. 
2001; Lawrie, Bryant et al. 2013). 
 
Liposomes are very effective delivery carriers due to their physical and chemical 
structures and their biocompatibilities (Lian and Ho 2001). These artificially 
prepared small carrier vesicles are made of lipid bilayer composed of natural or 
synthetic cationic lipids such as phospholipids or cholesterols (Lian and Ho 2001; 
Kudsiova, Ho et al. 2011). Synthetic vectors for DNA/RNA delivery offers advantages 
over viral systems in term of their greater nucleic acid packaging capacity, lower 
immunogenicity and greater safety (Somia and Verma 2000).  
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Size, charge and surface properties of liposomes can be changed by modifying 
components of the lipid mixture (Torchilin 2005; Mustapa, Bell et al. 2007). 
Liposome surface modification, such as the attachment of targeting peptide, can 
direct liposomes to certain pathological areas in the body; while the attachment of 
fluorescence molecules or radionuclides may serve for diagnostic imaging (see 
Figure 12) (Torchilin 2005).  












Figure 13: Overview of a liposomal vesicle. 
Water-soluble drugs are entrapped into the aqueous interior of the liposomes 
(a); while water-insoluble drug can be incorporated into the liposomal 
membrane (b). Protective polymer PEG can shield and stabilize the liposome 
complexes (c). Surface modification with specific proteins and ligands can be 
applied for targeting delivery (d). Attachment of the diagnostic labels allows 
monitoring the fate of liposomes (e). 
 
Modified from Torchilin (2005) Nat Rev Drug Discov. Volume 4, Issue 2, Pages 145-60 
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However, rapid clearance and degradation by the mononuclear phagocyte system, 
in particular those of the liver and spleen, is a major problem for the development 
of pharmaceutical nanoparticles (Cullis, Chonn et al. 1998). The flexible and 
hydrophilic polymer polyethylene glycol (PEG) can be incorporated into the lipid 
bilayer and stabilize the liposome structures, hence decrease their interactions with 
serum proteins and reduce inter-liposomes interaction to prevent aggregation. 
PEGylation of the liposomes prolongs in vivo circulating time compared to non-
modified liposomes, which enhances the opportunity to target tumours (Varga, 
Wickham et al. 2000; Maruyama 2002; Grosse, Tagalakis et al. 2010). 
 
The proliferation of new blood vessels and capillaries, referred as angiogenesis, is a 
common feature in rapidly growing tumour tissues and is necessary for the supply 
of fresh nutrients and growth factors. Liposomal nanoparticles with a size of several 
hundred nanometres could leak preferentially through the tumour vasculature as 
their sizes are close to that of vascular opening. Therefore liposomes could 
passively accumulate in the tumour region based on the ‘enhanced permeability 
and retention effect’, while passage is restricted by tight cellular junctions in normal 
tissue (Yuan, Dellian et al. 1995; Drummond, Meyer et al. 1999; Park and Yoo 2010). 
 
Traditional small-molecule cancer therapies suffer from limited selectivity between 
tumour and healthy tissues. With surface modification, liposomes can selectively 
target certain receptors in the tumour cells and deliver molecules, and enhance the 
retention of the liposomes due to bio-molecular interactions. Small structural 
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differences in the selection of targeting peptides for receptor recognition or LPD 
(DOTMA/DOPE lipid (L), peptide (P) and DNA (D)) ratio can result in pronounced 
differences in transfection within each type of receptor-targeted nanocomplexes 
(Torchilin 2005; Mustapa, Bell et al. 2007; Grosse, Tagalakis et al. 2010; Kudsiova, 
Ho et al. 2011). Different strategies have been applied for EGFR-targeting studies 
that include antibody conjugation or small peptides that mimic the natural ligands 
to demonstrate specific interaction with the receptor (Sofou and Sgouros 2008; 
Beuttler, Rothdiener et al. 2009; de la Rica, Aili et al. 2012). 
 
Moreover, the increase in size of the nanoparticles, due to for instance antibody-
conjugation, may significantly affect the targeting efficiency of liposomes. This is 
because nanoparticles of small size have much longer circulation time in vivo than 
larger ones. Antibody-conjugation may also alter the surface charge, hydrophobic 
or hydrophilic properties of liposomes, which contribute greatly to the stability and 
biologic activity of liposomes. All these properties should be put into consideration 
when designing liposomal complexes (Beuttler, Rothdiener et al. 2009).  
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Objective 1 – Characterisation of Picchu-X sensor 
The primary objective of the project was to characterise the CrkII-based biosensor 
(Picchu-X) in cellular system of basal-like breast cancer for its sensitivity on 
monitoring EGFR activation and inhibition. - see Chapter 4.1 
 
Objective 2 – High-content siRNA screen to identify regulators of EGFR signalling  
The next objective was to interrogate, using this biosensor, the key molecular 
factors within the selected protein subnetwork that are involved in EGFR signalling. 
We discussed here an in-house development of a semi-automated high-content 
screening system, which incorporated FRET-FLIM high-throughput microscopy 
(Fruhwirth, Fernandes et al. 2011; Matthews, Fruhwirth et al. 2012), in combination 
with RNAi-based knockdown technique utilising a library of siRNA consisted of 533 
genes. The aim was to identify genes that modulate EGF-induced biosensor 
conformational changes. - see Chapter 4.2 
 
Objective 3 – Liposomal delivery of biosensor to cancer cells in vivo 
Another vital aspect of this project involved the use of lipid-based nanoparticles to 
formulate serum-stable liposomes carrying EGFR-targeting peptides. These were 
used for in vivo delivery of the same biosensor, in order to study the intratumoural 
heterogeneity of EGFR activity and its modulation by known EGFR kinase inhibitor, 
in a murine model of basal-like breast cancer. - see Chapter 4.3  







CHAPTER 3: Material and Method 
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3. 1: Reagents 
 
Reagents for Cell Culture 
Dulbecco’s Modified Eagle Media - DMEM (Life Technologies Ltd) 
RPMI Media 1640 (Life Technologies Ltd) 
Minimum Essential Medium Eagle – MEME (Sigma-Aldrich) 
Full medias contain 10% Penicillin/ Streptomycin (10,000IU Penicillin and 
10,000µg/ml Streptomycin) (Life Technologies Ltd) 2mM L-Glutamine (Life 
Technologies Ltd), and 10% heat inactivated Foetal Bovine Serum (Sera 
Laboratories International Ltd) 
Trypsin/EDTA (0.25% trypsin, 0.02% EDTA) (PAA) 
 
Reagents for cellular transfection  
Opti-MEM-1 (Gibco) 
FuGene 6 (Roche Diagnostics) 
FuGene HD (Roche Diagnostics) 
Lipofectamine 2000 (Life Technologies Ltd) 
Lipofectamine RNAiMAX (Life Technologies Ltd) 
 
Reagents for Molecular Biology 
DH5α bacterial cells (Invitrogen) 
LB agar and LB broth (Sigma) 
Ampicillin (Sigma) used at 100µg/ml 
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Kanamycin (Sigma) used at 50µg/ml 
PureYield Plasmid Miniprep System Kit (Promega)  
PureLink HiPure Plasmid FilterMaxiprep Kit (Life Technologies Ltd) 
 
Ligands for receptors 
EGF: recombinant human epidermal growth factor (PeproTech, USA) used at 10 or 
100ng/ml 
HGF: recombinant human hepatocyte growth factor (R & D Systems) used at 
50ng/ml 
 
Cell signalling inhibitors 
PD168393 (Santa Cruz Biotech): anti-EGFR, used at final concentration of 10µM in 
DMSO 
Morpholino-IPQA (described in (Pal, Glekas et al. 2006; Medina, Pillarsetty et al. 
2011) synthesized in-house in the laboratory of Alethea Tabor at University College 
London): anti-EGFR, used at final concentration of 10µM in DMSO 
SGX523 (Millipore): anti-CMET, used at final concentration of 5µM in DMSO 
Lapatinib (LC labs, USA) was a kind gift from Professor Gyorgy Keri (Vichem Chemie 
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Reagents for Western Blotting 
Five-fold sample buffer: 100mM Tris (pH 6.8), 10% w/v SDS, 50% Glycerol; after 
protein determination in the sample, 100mM Dithiothreotol (DTT) and 0.002% w/v 
bromophenol blue were added 
Gels: 30% Acrylamide/Bis solution 37.5:1 (BioRad) ammonium persulphate (Simga) 
Precision Plus protein dual colour standard (BioRad) 
Running buffer: 25mM Tris Base, 0.19M glycine, 0.1% SDS 
Transfer buffer: 25mM Tris Base, 0.19M glycine, 20% w/v methanol 
Wash buffer: Tris-buffered saline (TBS): 0.02mM Tris, 0.05M NaCl, 0.01M KCl, pH 
7.4 
TBS-Tween (TBST): TBS containing 0.1% Tween-20 
Blocking solution: 4% Bovine Serum Albumin (BSA) (BioSera) made up in TBS-Tween 
Amersham Hybond ECL nitrocellulose membrane (GE Healthcare) 
Re-blot Plus (Millipore) 
Pierce ECL Western Blotting substrate (ThermoScientific) 
Coomassie stain: 0.25% w/v Coomassie brilliant blue R-250, 7% acetic acid, 40% 
methanol, made up to 1L in distilled water 
Destain solution (7% acetic acid, 10% methanol, made up to 1L in distilled water) 
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Primary antibody:  
Antibody Target Species Size (kDa) Company 
pEGFR Tyr 1173 rabbit 170 Millipore 
EGFR  mouse 170 Cell signaling 
HER2  mouse 185 Cell signaling 
pc-MET Tyr1234/1235 rabbit 145 Cell signaling 
c-MET  mouse 145 Cell signaling 
pCrkII Tyr 221 rabbit 42 Thermo Scientific 
CrkII  rabbit 42 Cell signaling 
pERK1/2 Thr 188 mouse 44/42 Cell signaling 
ERK1/2  rabbit 44/42 Cell signaling 
XRCC6  rabbit 70 Epitomics 
Tubulin  mouse 57 Sigma 
 
Secondary antibodies: Goat anti-rabbit antibody, used in 1: 2000; goat anti-mouse 
antibody, used in 1:3000 
 
Reagents for immunofluorescence staining 
Primary antibody: Alexa Fluor-647 anti-mouse CD31 antibody (BioLegend), used in 
1:200 
Rat anti-mouse F4/80 antibody (Abcam), used in 1:250 
Secondary antibody: Donkey anti-rat Cy5, used in 1:300 
Mowiol: 10% (w/v) Mowiol 4-88, 25% glycerol, 100mM Tris-HCl pH 8.5 (Calbiochem) 
DABCO: 2.5% (w/v) 1,4-diazabicyclo[2.2.2]octane (Sigma-Aldrich) 
TBS: Tris-buffered saline (25mM Tris, 100mM NaCl, pH 7.5)  
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4% (w/v) paraformaldehyde (PFA) (Sigma-Aldrich) 
Sodium Borohydride (Sigma-Aldrich) 
Immersol 510 Immersion oil (Zeiss) 
 
3. 2: Design and construction of Picchu-X biosensor 
 
Yellow fluorescent protein-CrkII-cyan fluorescent protein (YFP-CrkII-CFP) 
(Phosphorylation Indicator of Crk Chimeric Unit, Picchu) probes for reporting EGFR 
kinase activities in cells have been reported previously (Kurokawa, Mochizuki et al. 
2001; Itoh, Kurokawa et al. 2005; Aoki, Kiyokawa et al. 2008) and were obtained 
from M. Matsuda (Osaka University, Japan).  
 
The new Picchu sensor was modified by the excision of the sensor module between 
YFP and CFP, then inserting this module between the mRFP1 and eGFP, in the 
pEGFP-N1 vector (Clontech) that has been modified in-house by the addition of 
mRFP1 and altering the multiple cloning sites). The membrane targeting CAAX 
sequence of k-RAS was cloned after the eGFP as a plasma membrane-anchoring 
motif and named as Picchu-X, with the resulting construct maintaining the same 
linkers as the original. The resultant eGFP- and mRFP1-tagged Picchu-X constructs 
retain the original design of the CFP-YFP tagged version (reference (Itoh, Kurokawa 
et al. 2005) and http://www.lif.kyoto-u.ac.jp/labs/fret/e-phogemon/picchu.htm). In 
additional, control sensor lacking mRFP1 acceptor fluorophore, named Picchu-X-
GFP, was also constructed in the same manner. All constructs used in this project 
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were made by a prior member of my supervisor’s laboratory, Dr Melanie Keppler, 
and were verified by sequencing before use. 
 
3. 3: Plasmid purification and transformation 
 
DNA construct was transformed into DH5α competent cells and plated on Luria-
Bertani (LB) agar plates containing appropriate antibiotic (Ampicillin (1mg/ml) or 
Kanamycin (1mg/ml)). Bacterial colonies were incubated in LB medium (4ml for 
miniprep or 200ml for Maxiprep) and were allowed to grow overnight at 37°C. 
Miniprep and Maxiprep Kits were used to isolate plasmid DNA from bacterial 
cultures, following the manufacturer’s protocol (Protocol overview: cells were 
harvested from bacterial cultures by centrifugation and cell pellets were 
resuspended in buffer containing RNase A; cells were lysed and mixed with 
precipitation buffer then flowed through an anion-exchange column fitted with the 
filtration cartridge unit; cell lysates were clarified and negatively charged 
phosphates of the DNA backbone interacted with the positive charges on the 
surface of the anion exchange resin; DNA was eluted under high salt condition and 
was desalted and concentrated by alcohol precipitation using 70% isopropanol prior 
to centrifugation; DNA pellets were washed with 70% ethanol and were air-dried 
after centrifugation; DNA was resuspended in nuclease-free water). 
 
DNA extract was quantified and its purity was determined with NanoDrop 1000 
spectrophotometer (Thermo Fisher Scientific). For quantity, absorbance was 
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measured at 260nm and purity was determined by the ratio of absorption at 
260nm:280nm. Pure DNA has a ratio of between 1.8 and 2.0, while a ratio below 
1.8 shows high protein contamination. 
 
3. 4: Cell culture 
 
MDA-MB-231 and 293T were cultured in DMEM, HCC1954 was cultured in RPMI 
Medium 1640 and BT20 was cultured in MEME.  All media were supplemented with 
10% foetal bovine serum (FBS), 2mM L-glutamine and penicillin/streptomycin 
antibiotics. The cell cultures were kept at 37°C in humidified air containing 5% CO2. 
Media were changed frequently to remove dead cells and to refresh nutrients. The 
cells were split once they became 80-90% confluent. 
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3. 5: Transient transfection and cell treatments 
 
To achieve 50–80% confluence required for transfection, cells were plated at 2 x 105 
cells per 35mm culture dish (or 6-well-plate) for this cell density. FuGENE 6, FuGENE 
HD or Lipofectamine 2000 reagent were used for plasma DNA transfection. The 
number of cells for plating and the amount of DNA/reagent used were adjusted 
according to the table above. In occasions, to evaluate the cellular responses, cells 
were starved for 24hr before inhibitory or stimulatory treatments to retain cells in 
G0 phase of cell cycle. 
 
3. 6: Stable infection 
 
Cells with stable knockdown of EGFR or c-MET were provided by Dr Gregory 
Weitsman. In brief, viral particles (transfer vector, packaging vector, enveloping 
vector and Rev expressing vector) with specific or non-targeting shRNA were 
generated by transfection into 293T cell cultures. The supernatants, which 
contained viral particles, were collected and added to target cells for infection. 48hr 
post infection, medium were refreshed daily with puromycin selection (2µg/ml) for 
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five days for the selection of antibiotic resistant cells due to expression of 
expression of resistance gene associated with shRNA. 
 
3. 7: Protein expression- immunoblotting 
 
The expression of proteins was tested by western blotting. 2 x 105 cells were 
seeded in 6-well-plates. At 80% confluence, the monolayer of cells was then 
exposed to biochemical treatment of inhibitors or ligands. The cells were washed 
twice with ice-cold PBS and protein extracts were prepared in 1 X SDS lysis buffer 
solutions. Protein concentrations were measured by the BCA protein assay kit using 
known concentrations of BSA protein as standards. For immunoblot, cell lysates 
were heated at 95˚C for 15min in 100mM DTT reducing agent, then 
electrophoresed on self-made 7.5% Tris-glycine SDS-polyacrylamide gels. Gels were 
run on an Invitrogen X-Cell mini-gel system, which were subjected to constant 
voltage electrophoresis at 200V until the blue loading dye reached the bottom of 
the gel. 
 
After separation, proteins were electrophoretically transferred onto nitrocellulose 
transfer membrane at 300mAmp for 2hr on ice using the Invitrogen XCell II Blot 
Module. Membranes were blocked 45min in 4% BSA in TBS-Tween and then 
incubated with specific primary antibody overnight at 4oC followed by appropriate 
secondary antibody for 45min at room temperature. The blots were visualised 
using the ECL Western Blotting Substrate kit. It was possible to re-use the transfer 
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membrane for a second incubation with different primary antibody. The protein 
bound to the transfer membrane were stripped off with Re-BLOT Plus Strong 
solution, diluted 1:10 with TBS-Tween, for 15min at 37oC, followed by blocking and 
antibody incubation steps as above. Western blot results were analysed and 
normalised with Quantity One software (Bio-Rad Ltd). 
 
3. 8: Fixation protocol 
 
For cellular imaging experiments, cells that were seeded at 0.5 X 105 on glass 
coverslips were treated and fixed with 4% paraformaldehyde (PFA) in PBS for 
15min then rinsed thrice with PBS over a five minute interval. Samples were then 
incubated with sodium borohyrate (1mg/ml) for 5min to reduce auto-fluorescence 
and nuclei were stained with Hochst33342 at concentration of 0.1µg/ml. Coverslips 
were then mounted on slides with mowiol mounting medium mixed with 2.5% 
DABCO as an antifading agent, and dried overnight at room temperature. 
 
3. 9: In vitro liposomal transfection 
 
Synthesis of lipids and preparation of liposomes were performed by Dr. Nick 
Mitchell in University College London, while all the cellular and animal experiments 
were performed in my supervisor’s laboratory. 10µM liposome solutions, which 
contained 4µg of sensor plasmid DNA, were applied to cells at 60% confluence in 6-
well-plates. After 4hr incubation at 37°C, cells were washed twice with sterile PBS 
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to remove unbound liposomes and then incubated with normal growth medium for 
48hr to allow sensor protein maturation. 
 
3. 10: Xenograft model 
 
Four-week-old female Crl:CD1-Foxn1nu/nu mice were used for the experiments. 
Mice were kept in laminar flow isolators in the animal facilities at Guy’s Campus. 
1.5 X 106 cells were suspended in 50µl sterile PBS and were injected subcutaneously 
to the animals. Tumour volume was calculated using the formula v = l x (w) 2/2, 
where v = volume, l = length and w = width of tumour. After three weeks, tumours 
reached volume of approximately 40mm3 and 100µl liposome solutions in 5% 
glucose were injected into tail veins. Mice were monitored for 48hr post-
administration. EGFR tyrosine kinase inhibitor, Morpholino-IPQA, was suspended in 
sterile and filtered water at pH 6.5 (at 10mg/ml) and 100ul was delivered 
intravenously to the mice (32mg/kg). All procedures were done in accordance with 
UK Home Office legislation. 
 
4hr post-treatment of the inhibitor, solid primary tumours were dissected out and 
rapidly frozen in liquid nitrogen and stored at -80°C until further use. Frozen 
tumours were cut into 4µm sections with a cryostat for immunostaining and 
multiphoton (MP)-FLIM imaging experiments of the fluorescent biosensors as 
described previously (Festy, Ameer-Beg et al. 2007; Beutler, Makrogianneli et al. 
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2008; Makrogianneli, Carlin et al. 2009; Heasman, Carlin et al. 2010; Carlin, Evans et 
al. 2011; Matthews, Fruhwirth et al. 2012). 
 
3. 11: Immunostaining for blood vessel and macrophage 
 
Ex-vivo tissue samples were stained with Alexa Fluor-647 anti-mouse CD31 
antibody to correlate Picchu-X activity to distance to blood vessels; while F4/80 
antibody (secondary antibody: donkey anti-rat Cy5) were used for the staining of 
macrophages. Samples were fixed with 4% PFA in PBS for 15min then incubated 
with sodium borohydride (1mg/ml) for 10min to reduce auto-fluorescence. They 
were then blocked in 1% BSA for one hour then washed thrice before adding 
fluorophore-labelled CD31 antibody for an hour and placed in dark room 
(secondary antibody for F4/80 was needed and applied for an additional 45min). 
After washing, the solution of Hochst33342 was used for DNA staining and then 
samples were mounted in mowiol mixed with 2.5% DABCO. 
 
3. 12: Confocal microscopy 
 
Confocal fluorescence images were acquired on a confocal fluorescence laser-
scanning microscope (model LSM 510; Carl Zeiss Inc.) equipped with 40X/1.3Plan-
Neofluar and 63X/1.4Plan-APOCHROMAT oil immersion objectives, or a Leica 
DMIRE2 (Leica Microsystems, Germany). Confocal aperture was set to one Airy unit 
for the longest wavelength. The various colour filters that were used for detecting 
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the different fluorophores are as follow (excitation wavelength): DAPI (405- 
450nm), FITC (488- 510nm), Cy3 (543- 573nm) and Cy5 (633- 738nm). Images were 
analysed using the LSM Image Brower software. 
 
3. 13: siRNA knockdown 
 
Cells were transfected with 10nM of siRNA using Lipofectamine RNAiMAX according 
to the manufacturer's protocol. Control cells were treated with scrambled negative 
control siRNA sequence. Cells were grown and harvested 72 hours after the 
transfection. 
 
3. 14: Preparation of high-content siRNA screen using automated liquid handling 
robot 
 
For the high-content siRNA screen, JANUS Automated Workstation (PerkinElmer) 
was employed for the efficient automation of sample preparation. Its dual-arm 
system offered a 96-tip Modular Dispense Technology (MDT) Dispense Head or a 4-
tip Dispense Arm for optimal precision pipetting, processing from tubes to vials to 
plates.  
 
A library of siRNA targeting 533 genes encoding for proteins that interact with 
HER1-4 as seed proteins directly or indirectly; was chosen from the HPRD (please 
refer to (Fruhwirth, Fernandes et al. 2011) for a description of the bioinformatics 
techniques involved in selecting these genes).  A set of three different siRNA 
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sequences were purchased for the targeted knockdown of each gene (Ambion). 
The primary 1nmol stock of the siRNA library was diluted 500 times in three steps 
for storage: ten times to create first-level dilution, then five times to create second-
level and finally ten times to create third level dilution), which generated 
2pmol/10µl/well in 96-well-plate format for third-level dilution plates that were 
used for cell transfection.  
 
Lipofectamine RNAiMAX at the ratio 2:1 were robotically pipetted to third-level 
dilution plates and incubated with siRNA for 20min; meanwhile, cells were seeded 
into 384-well-plates (4000 cells/well). The transfection mixtures were added onto 
cells, each set of siRNA were aliquoted in duplicates (10nM final siRNA 
concentration) and the transfected cells were incubated at 37 oC. After 24hr, 
Fugene HD transfection reagent was used to transfect sensor plasmid DNA in 3:1 
ratio. Cells were incubated for additional 48hr for sufficient gene knockdown and 
sensor protein maturation.  
 
Prior to fixation, EGF (100ng/ml) was added to one of the siRNA replicate well, 
while the other replicate well left untreated. Plates were washed twice and fixed 
with 4% paraformaldehyde (PFA) for 15min then rinsed thrice with PBS. Samples 
were then incubated with sodium borohyrate (1mg/ml) for 10min to reduce auto-
fluorescence. After further three washes, mowiol mounting medium mixed with 
2.5% DABCO was added directly into the plates (50µl/well). Plates were stored at -
20 oC until imaging.  
| - 89 -  
 
  
3. 15: Single-photon FLIM/ epi-fluorescence microscope (automated systems were 
named Galileo and Hooke) 
 
Lifetime and epi-fluorescence images of in vitro biosensor-transfected cells were 
captured on single-photon microscopy system that was developed and built in-
house. The FLIM component of the system consists of a dual axis scanning system, a 
PMT detector (PMH-100, Becker and Hickl) and time-correlated single photon 
counting (TCSPC) detection (SPC830, Becker and Hickl). Fluorescence excitation is 
provided by a board spectrum Fianium laser which generates optical pulses with a 
duration of 40ps at a repetition rate of 80MHz. Single photon, time-resolved 
fluorescence is detected at 510±20nm using a photomultiplier tube (PMH-100, 
Becker and Hickl) with a 20x S-Fluor (NA 0.75) objective. The second mode of 
operation is a simple epi-fluorescence microscope, which consists of the output 
from lamp coupled into the microscope using a liquid light guide and a CCD camera 
for detection of fluorescence emission. Automated operation is achieved by 
incorporating a motorised microscope stage (Märzhauser GmbH, Wetzler, 
Germany), a closed-loop objective lens mount with a 500µm range of travel 
(Piezosystem Jena GmbH, Jena, Germany) and a motorised filter cube selector. 
 
 Semi-automated high-content SP-FLIM imaging 
 
Five points on each well of the imaging plates were logged manually prior to data 
acquisition, and then imaged in a fully automated fashion. The automated system 
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saved operator marked x, y and z coordinates for each point. On completion of field 
of view marking, the system returned to each core and focussed using a high 
precision (auto-focus in 0.2µm lateral resolution) computer-controlled objective 
stage (Piezo-system), then imaged consecutively in the FITC cube for eGFP 
detection, the Cy3 cube for mRFP1 detection and the UV cube for auto-
fluorescence or nuclear staining. The auto-exposure routine was also employed. 
The system saved all three images then switched automatically to laser-scanning 
mode to acquire the single photon data and save time-resolved images. FLIM 
images have 256 x 256 pixel resolutions and ADC was set to 64 time channels. 
 
3. 16: Time-resolved multi-photon microscopy 
 
Ex-vivo tissue section imaging was performed on multi-photon microscope system, 
comprising a solid-state pumped (8-W Verdi; Coherent), femtosecond self-
modelocked Ti:Sapphire (Mira; Coherent) laser system, an in-house developed 
scan-head, and an inverted microscope (Nikon TE2000E, x40 oil objective) (Peter, 
Ameer-Beg et al. 2005; Barber, Ameer-Beg et al. 2009).  
 
Imaging data comprised of 256x256 pixel resolution and 256 time channels. This 
arrangement facilitates analysis using multi-exponential decay models. FRET 
efficiency was calculated according to equation: FRET efficiency = 1- τda/τcontrol, 
where τda is the lifetime of eGFP in cells that co-express mRFP1 and τcontrol is eGFP 
lifetime measured in the absence of acceptor. Since sub-100 ps time resolution is 
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achieved with our instrumentation, for a τcontrol value of 2.35 ns, FRET efficiencies as 
low as 3% can be determined accurately. Pixel-by-pixel lifetime determination was 
achieved using a modified Levenberg-Marquardt fitting technique (Barber, Ameer-
Beg et al. 2005). For cases where sufficient reduction in the measured lifetime 
allows the separation of two distinct, spatially invariant, GFP lifetime 
subpopulations, i.e. non-interacting (τcontrol) and interacting (τFRET), an additional 
analysis was performed. Applying a bi-exponential fluorescence decay model and 
global analysis techniques to the data enables the determination of τcontrol and τFRET, 
and their pre-exponential factors (or relative concentration) on a pixel-by-pixel 
basis (Barber, Ameer-Beg et al. 2009). The FRET population F2 is the fraction of 
interacting molecules that exhibit τFRET according to the equation τFRET = FRET Eff/[1 
- (τFRET/τcontrol)], since τda = F2 x τFRET +  (1 – F2) x τcontrol.  
 
3. 17: Analytical Methods  
 
FRET-FLIM Analysis 
The fluorescence lifetime was calculated by fitting exponential fluorescence decay 
models to the images. The FLIM images obtained with the lifetime microscope were 
batch analysed by a PC workstation running in-house exponential fitting software 
(TRI2) written in CVI by Dr Paul Barber (Barber, Ameer-Beg et al. 2009). The 
program outputs files where all the fitting parameters were recorded for each 
image. These files were then analysed to produce a distribution of lifetime and an 
average lifetime. The analysis has been made robust to noise and to low photon 
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counts, providing fast execution and amenability to automation and batch 
processing. All cellular lifetime data acquired with SP-FLIM was fitted with the 
single exponential decay analysis, while all tissue lifetime data acquired with MP-
FLIM was fitted with bi-exponential decay model. Data were expressed as means ± 




SPSS Statistics 19.0 was used to analyse the association between donor eGFP 
fluorescence lifetime (Tau), intensity, and EGF treatment for each siRNA knockdown 
using linear regression model, where Tau= slope*intensity + intercept. Pearson 
correlation coefficient (r) was reported for the association between tau and lifetime. 
To observe the effect of EGF towards this association, a linear regression model 
which included an interaction term with EGF (dichotomous values, where EGF=0 or 
EGF=1, resulting in two linear equations of individual lines) was used to determine 
whether the effect of intensity on Tau differed by EGF status. A T-test was reported 
for the association between EGF and Tau and intensity, if the p value was < 0.05 
then there was a statistically significant interaction.  







CHAPTER 4: Result 
4.1: Characterisation of Picchu-X sensor 
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Chapter introduction - Characterisation of Picchu-X sensor 
 
The primary objective of the project was to characterise a range of new FRET-based 
sensors by which the CFP and YFP in the original probes were cleaved and replaced 
with eGFP and mRFP1 as the donor and acceptor fluorophore pair. 
 
Biosensors that report on the enzymatic activities of Akt (Yoshizaki, Mochizuki et al. 
2007) and EGFR (section 3.2), or levels of PIP2 and PIP3 (Aoki, Nakamura et al. 
2005), respectively, were validated in cell based system for their accuracy and 
sensitivity on the simultaneous detection of the activation for their specific 
signalling pathway(s). The CrkII-based sensor reporting EGFR activity, namely 
Picchu-X, was selected for further studies due to its robustness of reproducibility of 
monitoring EGFR activity under different conditions. 
 
The biochemical and FLIM-imaging data to confirm the functional aspects of Picchu-
X sensor in a variety of basal-like breast cancer cell-lines that overexpress EGFR are 
presented here in Chapter 4.1. The sensor was then used to conduct a high-content 
FLIM screen utilising a library of siRNA consist of 533 genes interconnected with 
EGFR (see Chapter 4.2); and was further used to test intratumoural EGFR activity 
using a liposomal delivery method in a murine model of basal-like breast cancer 
(see Chapter 4.3). 
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Result figure 4.1.1: Effects of specific EGFR tyrosine kinase inhibitor, Morpholino-
IPQA and its precursor PD168393. 
(A) EGFR tyrosine kinase inhibitors, Morpholino-IPQA (Mo-IPQA) and PD168393 (PD), 
interact irreversibly with the ATP-binding site of activated EGFR domain. The 
bromide group of PD168393 is replaced with an iodine group in Morpholino-IPQA, 
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 (B) MDA-MB-231 and HCC1954 cells were treated with 5, 10 or 20µM of PD168393 
(PD) or Morpholino-IPQA (Mo-IPQA) for one hour before adding EGF (100ng/ml) for 
30min, prior to lysis. Immunoblots were carried out using the antibodies indicated 
above. Histograms represent the phosphorylation level of EGFR and ERK1/2, 
normalised to total expression of the respective protein. 
(B)  
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Result figure 4.1.2: EGF-induced activation of EGFR and corresponded Picchu-X 
activity. 
(A) HCC1954 cells were seeded in 6-well-plate and transfected with Picchu-X 
plasmid DNA. After 48hr, cells were treated with EGF (100ng/ml) for up to 30min, 
prior to lysis. Immunoblots were carried out using the antibodies indicated above. 
(B) Western blot results were analysed and normalised with Quantity One 
software. Line graph represents the phosphorylation level of EGFR and CrkII, 




























EGF stimulation (min) 
pEGFR/tEGFR 
pCrkI/tCrkII 
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Inhibition of EGFR activity using specific EGFR tyrosine kinase inhibitor  
A number of EGFR over-expressing basal-like breast cancer cell-lines, MDA-MB-231, 
HCC1954 and BT20, were chosen for the study due to their abnormal EGFR tyrosine 
kinase activity, causing the aggressive cancer development and progression. We 
carried out inhibitory experiment using a specific, irreversible EGFR tyrosine kinase 
inhibitor, Morpholino-IPQA (Mo-IPQA) (Gelovani 2008) to investigate its EGFR 
inhibition ability compared to its precursor PD168393 (Fry, Bridges et al. 1998). 
 
PD168393 is a cell-permeable and selective inhibitor of EGFR tyrosine kinase 
activity. It binds irreversibly to the catalytic domain of the activated EGFR domain 
with a 1:1 stoichiometry, alkylates the Cys773 group and blocks the binding of ATP 
by pointing its bromide group into the hydrophobic pocket of the ATP-binding 
pocket, hence prevents receptor activation (Fry, Bridges et al. 1998) (Gelovani 
2008). The IC50 values of PD168393 for EGFR autophosphorylation were at 
approximately 11.1 nM (Chen, Kovar et al. 2005). The bromide group can be 
replaced with an iodine group, to form Morpholino-IPQA, which can interact 
irreversibly with the receptors (Result figure 4.1.1A). This compound was 
synthesized in-house in the laboratory of Alethea Tabor at University College 
London (please see appendix for the synthesis and purification of Morpholino-IPQA). 
The iodine group in Morpholino-IPQA can be replaced with radioactive iodine and 
be explored as a potential radiotracer for the molecular imaging of EGFR 
overexpressing tumours (Pal, Glekas et al. 2006). This will be discussed further in 
the Discussion Chapter. 




In the two basal-like breast cancer cell lines, MDA-MB-231 and HCC1954, inhibitors 
were applied at 5µM, 10µM or 20µM for one hour followed by EGF stimulation 
(100ng/ml).  
 
A potent inhibitory effect was observed with the PD168393 treatment. At all three 
concentrations there were more than ten-fold decreases in the phosphorylation of 
EGFR comparing to EGF stimulation alone, confirming the blockade of ligand 
binding to the receptors (Result figure 4.1.1B, lane 3, 4 and 5). For Morpholino-
IPQA, immunoblot revealed small a dose-related increase in inhibition (lane 6, 7 
and 8) and 10µM dose was selected for future experiments. 
 
Interestingly, although the phosphorylation of EGFR was significantly inhibited in 
both cell-lines, the level of phosphorylated ERK1/2 remained high after the 
inhibition by Morpholino-IPQA as shown in result figure 4.1.1B. The inhibitor was 
washed away using sterile PBS before the stimulation of EGF, this indicated that the 
with the inhibition of Morpholino-IPQA, a small amount of receptors were still be 
able to get phosphorylated by the nature ligand, and only a small number of active 
receptors were required to activate a cascade of downstream signalling pathways, 
resulting in an increase of ERK1/2 activity. As demonstrated in Chen et al., the 
concentration of inhibitor required to inhibit the phosphorylation of downstream 
molecules such as ERK1/2 was usually much higher than needed for EGFR. 
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EGF-induced activation of EGFR and corresponded Picchu-X sensor activity 
Result figure 4.1.2 demonstrated the tyrosine phosphorylation of the CrkII-based 
sensor upon EGF stimulation and its association with EGFR activity. The molecular 
weight for CrkII protein was 42kDa. A part of the C-terminal SH3 domain was 
cleaved by restriction enzyme for the construction of Picchu-X sensor (CrkII amino 
acids 1–236); however it would not affect the phosphorylation of Tyr221. The 
molecular weight of the CrkII-based sensor was expected to be approximately 
90kDa (with eGFP and mRFP1 fluorescent proteins flanking on each terminal of the 
CrkII protein). However, instead of a single 90kDa band of the Picchu-X sensor, a 
double band was observed in the immunoblots in the region of 80kDa protein size. 
This was due to the partial fragmentation of the red fluorescent protein upon 
heating at 95°C for 15 minutes during sample preparation, which seems to be a 
common effect on DsRed-like fluorophores (Gross, Baird et al. 2000).  
 
In HCC1954 basal-like breast cancer cells, EGFR phosphorylation peaked at 3min, 
followed by the activation of its downstream adaptor protein CrkII (as in Picchu-X 
sensor), which activity slowly increased over time and maximal by 30min after EGF 
stimulation (Result figure 4.1.2). This result confirmed that the activity of Picchu-X 
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Result figure 4.1.3: Quantification of lifetime measurements of Picchu-X 
(A) MDA-MB-231 and HCC1954 cells were transfected with Picchu-X plasmid DNA. 
After 48hr, cells were treated with PD168393 (10µM) for one hour. Images are 
representative of cells seen, white scale bar represents 10µm. (B) Quantification 
of lifetime measurements of Picchu-X or Picchu-X-GFP for MDA-MB-231, HCC1954 
and BT20 cells, before and after treatments with PD168393 (10µM) for one hour. 
Data were expressed as means ± SEM, statistical significance was analysed using 
unpaired two-tailed Student’s t-test.  
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Fluorescence lifetime measurement of Picchu-X sensor activity 
FRET-FLIM imaging of Picchu-X sensor in individual cells allow us to study the spatial 
and temporal activation/regulation of EGFR activity on a single cell level. To 
examine the dynamic range of the sensor in its open (inactive) or closed (active) 
state, we performed fluorescence lifetime measurements in both absence and 
presence of the EGFR kinase inhibitor, in this case PD168393 (Result figure 4.1.3). 
 
The introduction of eGFP/mRFP1 fluorophore pair have been proven to be a better 
suitable pair for donor FRET-FLIM assays, whereas mRFP1 has lower aggregation 
problems to form oligomers and has little or no green component in its 
fluorescence emission. This solved the problem of emission cross-talk, since eGFP 
can be excited at a wavelength beyond the excitation spectrum of mRFP1. In 
addition, eGFP is a photo-stable fluorophore that displays mono-exponential 
fluorescence decay, offering multiple advantages over the CFP/YFP pairs (Peter, 
Ameer-Beg et al. 2005).  
 
Result figure 4.1.3A demonstrated SP-FLIM images of MDA-MB-231 and HCC1954 
cells in their basal activity and in response to PD168393 treatment. Basal active 
Picchu-X activity was represented in the lifetime colour maps with yellow/green 
colours, whereas low activity was represented as blue colour and area with a low 
signal-to-noise ratio on which a lifetime measurement cannot be achieved was in 
black. 
 
| - 104 -  
 
  
In MDA-MB-231 cells, Picchu-X exhibited an increase in lifetime (from average basal 
lifetime of 1.86ns to 1.92ns) in response to EGFR inhibitory treatment. In contrast, 
control Picchu-X-GFP sensor (without expression of acceptor mRFP1) recorded a 
maximum lifetime of 2.06ns and remained the same in the presence of inhibitors. 
Similar response was observed in other two basal-like breast cancer cell-lines, 
HCC1954 and BT20 (Result figure 4.1.3B).  
 
On the technical side, it was easier to characterize the FRET signal from intra-
molecular biosensors as they were built with one donor and one acceptor, the 
stoichiometry was guaranteed to be 1:1 and thus they were less sensitive to the 
relative concentration than inter-molecular sensors. However, notably, these data 
indicated that the dynamic ranges of this type of intra-molecular FRET-based 
sensors were quite narrow, mostly with less than 0.1ns changes in lifetime (this 
issue will be further discussed in Result figure 4.2.5). In spite of that, the increases 
in Picchu-X sensor lifetime in response to inhibitor treatment were reproducible in 
a variety of human cancer cell types (MDA-MB-2231, HCC1954, BT20, MDA-MB-468, 
SW1222 and Hela cells, data was not include in here).   











(B)    
Result figure 4.1.4: Effect of ligands and inhibitors on EGFR phosphorylation and 
FRET efficiency 
(A): HCC1954 cells were transfected with Picchu-X plasmid DNA. After 48hr, cells were 
treated with 10µM of inhibitor (PD168393, SGX523 or Lapatinib) for one hour, or with 
stimulant (EGF, 100ng/ml; HGF, 50ng/ml) for 30min, prior to lysis. Immunoblots were 
carried out using the antibodies indicated above. Western blot results were analysed 
with Quantity One software. (B) FRET efficiency measurement for the effect of 
inhibitor or stimulant treatment. FRET efficiency correlated to lifetime measurement = 
1- τ donor-acceptor/τ donor. 
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Picchu-X sensor activity upon ligand stimulation and receptor inhibition 
The purpose of this experiment was to examine the sensitivity and specificity of the 
Picchu-X sensor. As with most signalling molecules, it was known that more than 
one signal pathway could contribute to the activity of the CrkII protein 
(Kobashigawa, Sakai et al. 2007).  
 
We applied recombinant human hepatocyte growth factor (HGF) and SGX523, a 
small molecule ATP-competitive kinase inhibitor that stabilised the inactive 
conformation of c-MET catalytic domain (Buchanan, Hendle et al. 2009), and 
measured the activity of EGFR and Picchu-X sensor in HCC1954 cells in order to 
determine the regulation between EGFR, c-MET and the CrkII-based sensor (Result 
figure 4.1.4). 
 
Since Picchu-X sensor was a direct target for EGFR kinase activity we assessed the 
FRET efficiency changes upon stimulations with EGF. As shown in Result figure 
4.1.4A, EGF caused activation of EGFR with the increased phosphorylation of 
Tyr1173 (second lane), which corresponded to the shift to the right of FRET 
efficiency histogram indicating the change from 4% to 9% (4.1.4B). FRET efficiency 
was calculated according to the equation = 1- τ donor-acceptor/τ donor.  
 
Apart from the c-MET inhibitor (SGX523), all the FRET efficiencies in cells treated 
with the other TKIs (such as the EGFR inhibitor PD168393 or EGFR-HER2 dual 
inhibitor Lapatinib) were similar to that observed in untreated control, in 
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agreement with the phosphor-EGFR immunoblots in 4.1.4A. The effect of various 
inhibitors on EGF-stimulated increase in Picchu-X activity will need to take into 
account the intensity-dependent lifetime time quenching effect, which will be 
described in a subsequent section Result figure 4.2.5.  
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Impact of c-MET signalling pathway on sensor activity 
As HGF is not a natural ligand for EGFR, it was clear that from the immunoblot there 
was no increase in phosphorylated-EGFR after HGF treatment (fourth line, Result 
figure 4.1.4A). However, there was an increase in FRET efficiency of the sensor, 
hinting an interaction of CrkII protein with activated c-MET. Interestingly, a TKI for 
c-MET also caused the phosphorylation of EGFR (and increased sensor activity) as 
judged by phosphorylation level in the immunoblot (fifth line, Result figure 4.1.4A).  
 
My supervisor (in collaboration with Prof. Yossi Yarden (the Weizmann Institute of 
Science, Rehovot, Israel) previously demonstrated in breast cancer cells, the 
conformational effects of anti-EGFR TKIs (Erlotinib and Gefitinib), in inducing 
EGFR:EGFR homodimer formation (Bublil, Pines et al. 2010). Lapatinib, another TKI 
that dually targets EGFR and HER2, has been shown by our laboratory and others to 
enhance the formation of HER2:HER3 heterodimer through an 
allosteric/conformational mechanism (Scaltriti, Verma et al. 2009; Patel 2013); 
which we have shown to lead to HER3 rephosphorylation, a known drug resistance 
mechanism that occurs in tumour cells under long term TKI treatment pressure 
(Sergina, Rausch et al. 2007; Amin, Sergina et al. 2010; Garrett, Olivares et al. 2011). 
The underlying mechanism and significance of anti-c-MET TKI-induced EGFR 
phosphorylation/activation are the subjects of further investigation in my 
supervisor’s lab but this is beyond the scope of this thesis. 
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Presently, the major application of Picchu-X sensor has been published as a 
reporter of EGFR tyrosine kinase activity, however it was known that other 
signalling pathways can affect the sensor activity (Kurokawa, Mochizuki et al. 2001). 
Cipres et al. have demonstrated that c-MET signalling could induce phosphorylation 
of CrkII on Tyr221, and this phosphorylation was mediated by Abl tyrosine kinase 
activity (Cipres et al, 2007). Furthermore, Trusolino et al. has showed an indirect 
association of CrkII and c-MET through the large docking protein Grb2-associated 
binding protein 1 (GAb1) (Trusolino, Bertotti et al. 2010). The mechanism by which 
c-MET associated with the EGFR remained to be determined. The activation of 
platelet-derived growth-factor receptor β (PDGFβR) signalling pathway might also 
contribute to sensor activity, which played fundamental roles in actin cytoskeleton 
remodelling and cell migration (Antoku and Mayer 2009).  
 
  





By monitoring the sensor conformation changes with FRET-FLIM, we could 
indirectly detect the EGFR activity related molecular events, such as the stimulation 
of ligand binding and the inhibition with small molecule inhibitors, and monitor the 
cellular signalling pathways. Furthermore, sensor might undergo conformational 
changes by the endocrine signals. However when the sensory domain was activated 
by EGF-triggered activation of EGFR, it would induce a large overall conformational 
change that changed the FRET signal. 
 
The Picchu-X sensor was selected to be employed in a large scale siRNA screen 
against a protein network consisted of 533 genes. It would be important to design 
these experiments carefully based on the sensitivity and specificity of the sensor. 
These data can potentially served as system response profiles of the cells to provide 













4.2: High-content screen of 533 genes interconnected 
with EGFR 
  
| - 112 -  
 
  
Chapter introduction - High-content screen of 533 genes interconnected with 
EGFR 
 
The next objective was to use an in-house semi-automated protein activity 
sensing/imaging technique to interrogate the EGFR-centric subnetwork of proteins, 
in order to obtain a better understanding of what molecular factors involved in the 
regulation of EGFR activity upon stimulation with EGF. 
 
A library of siRNA targeting genes interconnected with EGFR directly or indirectly 
(up to second degree of interaction), was chosen from the Human Protein 
Reference Database. Three different sequences were available for the silencing of 
each 533 genes. To exploit this library, we developed a high-content SP-FLIM screen 
using the Picchu-X sensor (described in previous chapters) in HCC1954 basal-like 
breast cancer cells. 
 
In this result section, we will describe the development of the screening procedure 
and the statistical analysis method to interpret the complex and large amount of 
FRET-FLIM data generated. 22 target genes (4.1% of the siRNA library) were 
identified as modulators of EGFR response to natural ligand. A couple of the genes 
were selected for further validation to establish the biological importance of the 
genes identified as primary hits in the EGFR signalling network. 
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Result figure 4.2.1: Indication of successful siRNA transfection into HCC1954 cells. 
(A) 10nM BLOCK-iT Alexa 555 Fluor-Red fluorescent oligo were transfected into 
HCC1954 cells using Lipofectamine RNAiMAX transfection reagent, scale bar 
represents 40µm. Images were obtained 72hr post-transfection. (B) HCC1954 cells 
were transfected with 10nM non-targeting siRNA (siNT) for 72hr, or siRNA against 
EGFR or HER2 for either 48hr or 72hr in duplicates. 
| - 114 -  
 
  
Since MDA-MB-231 and BT20 cells were proven to be difficult to transfect 
efficiently in small format of 384-well plate and were not strongly attached to 
substratum leading to loss of cell during the fixation procedure, we use HCC1954 
cells which grow at a fast rate and have superior transfection efficiency. 
 
siRNA transfection efficiency 
Successful gene silencing in siRNA-mediated RNA interference experiments 
required efficient uptake of siRNA into the cells. Two verification experiments were 
done to confirm successful transfection and gene knockdown.  
 
BLOCK-iT Alexa Fluor red fluorescent oligo (10nM) was transfected into HCC1954 
cells to enable the visualization of transfected dsRNA oligomers (Result figure 
4.2.1A). This reverse transfection method using Lipofectamine RNAiMAX reagent 
has been proven to be a rapid and effective method for cellular lipid-mediated 
siRNA delivery. After proving the effectiveness of uptake, we verified the release 
and knockdown efficacy of the siRNA by immunoblotting, showed in Result figure 
4.2.1B. In addition to control scrambled negative control siRNA sequence, EGFR and 
HER2 siRNA were transfected into cells.  The expression level of the receptor 
protein was assessed after 48hr and 72hr of knockdown to ensure efficient gene 
silencing. 
  






Result figure 4.2.2: Decrease in lifetime measurement after long hour of 
acquisition. 
HCC1954 cells were seeded in 384-well-plate and transfected with library of siRNA. 
After 24hr, cells were transfected with (A) Picchu-X or (B) Picchu-X-GFP plasmid 
DNA and were fixed 48hr later. Lifetime images were acquired with SP-FLIM. 
Acquisition time for each image was 150sec. Data was analysed using TRI2 software. 




Result figure 4.2.3: Plate-well design for the siRNA screen. 
The content of each siRNA-library plate was divided into two 384-well-plates for 
SP-FLIM imaging. Library of siRNA or non-targeting siRNA (10nM) was transfected 
into each set of neighbouring-wells (well number 1 and 2) containing HCC1954 
cells. After 24hr, cells were transfected with Picchu-X or Picchu-X-GFP plasmid 
DNA and allowed further 48hr for the sensor protein to mature. Cells on well 
number 2 were then treated with EGF (100ng/ml) for 30min before fixation. 
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As anticipated, the development of this large-scale protein activity screen using 
FRET-based biosensor has been proven to be a major challenge. The initial review of 
the screen data revealed a series of flaws that fall into a few categories, which 
included (1) experimental layout, (2) image acquisition and (3) data analysis. One 
must standardise the screening condition carefully and design appropriate data 
analysis method to generate result in a meaningful way throughout the whole 
screening process.  
 
(1) Experimental layout 
The application of time-correlated single-photon counting (TCSPC) detection for 
FLIM imaging has been proven to be a powerful technique to give high resolution 
and sensitive readout of the donor fluorescence lifetime signals. However, long 
acquisition time is required to achieve reliable photon statistics. The siRNA screen 
was performed in 384-well plates and typically up to five minutes was required to 
capture each image. Result figure 4.2.2 illustrated the problem with such long 
acquisition period. The scatter plot showed a gradual decrease in lifetime in the 
first 24 hours, followed by a much sharper decay for the rest of the samples. This 
drop in lifetime occurred in both samples transfected with Picchu-X (4.2.2A) and 
control donor sensor without the mRFP1 acceptor (4.2.2B), suggesting presence of 
problem is not related to the presence or absence of the FRET acceptor. When we 
analysed the images carefully, we noticed a significant decrease in signal to 
background ratio in samples that were imaged in prolonged acquisition overnight. 
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For our standard cellular imaging experiments, cells were usually plated on glass 
coverslips and mounted on slides with mounting medium (Mowiol) mixed with 
DABCO (an antifading agent to prevent photobleaching). The medium was 
hardened as it dried overnight. For the screening experiment, medium remained in 
aqueous form inside 384-well-plate at room temperature due to the volume and 
geometry of the well, and this might be the reason affecting lifetime measurements 
with the increasingly unstable noise level over time. This made it very difficult, if 
not impossible, to compare data obtained from different regions in the optical plate. 
 
In Result figure 4.2.3, we presented the reconstruction and optimisation 
procedures that enable us to reduce systematic errors, including plate-to-plate, 
temporal and spatial variability. Aliquoted siRNA solutions ready to use in 
experiment were store in 96-well-plates and contained 88 siRNA sequences with 
last column free, each well contained reagent that was directed to only one gene. 
This 96-well-plate was used to make two 384-well-plates to reduce the acquisition 
time for each 384-well-plate (see the plate layout in Result figure 4.2.3). The siRNA 
treated cells was aliquoted in duplicate; one replicate well left untreated, while the 
other replicate well would be treated with EGF (100ng/ml) subsequently in order to 
access EGF-induced biosensor conformational changes. This way, we eliminated the 
possible contribution of position in plate and time delay between two acquisitions, 
allowing us to access the effect of gene knockdown by analysing data obtained from 
individual set of neighbouring wells. 
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Multiple control wells were also present in the end of each assay plate. Control cells 
were treated with scrambled siRNA sequence and should not affect sensor 
activation after EGF treatment. Cells transfected with Picchu-X-GFP sensor (with 
mRFP1 acceptor cut out from the sequence) were used to calculate FRET efficiency 
according to the equation = 1- τ donor-acceptor/τ donor. Furthermore, only the 
inner 240 wells were used for imaging to reduce edge-effects and all pipetting steps 
were performed using the JANUS Automated Workstation to minimise pipetting 
















Result figure 4.2.4: The principle steps for the high-content SP-FLIM 
experiment with a library of siRNA consisting 533 genes interconnected with 
EGFR. 
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Result figure 4.2.4 demonstrated a simple workflow of the high content siRNA 
screen comprised into five different steps: reverse transfection of the library of 
siRNA, transfection of sensor DNA, stimulation of EGFR, fixation and image 
acquisition by SP-FLIM.  
 
We conducted a primary screen applying pools of three individual non-overlapping 
siRNAs against the same gene in one well, by which each sequence was presented 
at one-third of the original concentration. 1599 siRNAs for 533 genes were pooled 
in seven 96-well-plates (the first six plates contained 88 genes and the seventh 
plate contained only 5 genes). Several siRNAs should give the same phenotypic 
outcome but extremely unlikely to have the same off-target effects, therefore the 
risk of unwanted off-target effects was lowered in the pools with the reduced 
concentrations of individual siRNA sequences (3.33nM), while keeping the total 
concentration of siRNA molecules targeting the desired gene (10nM) (Krausz 2007).  
 
The library of pool siRNA was robotically transfected into HCC1954 cells and sensor 
DNA was transfected on the second day. After 72hr of gene silencing and 48hr of 
sensor protein maturation, one of the duplicate well was treated with EGF before 
fixation of the plates. Fluorescence and lifetime images were acquired using in-
house semi-automated SP-FLIM.   

















































Result figure 4.2.5: Correlation between biosensor lifetime and fluorescence 
intensity. 
Representative image of HCC1954 cells transfected with Picchu-X sensor, white 
scale bar represents 40µm. Images required ‘cell masking’ analysis (A) to extract 
individual values of fluorescence lifetime and intensity and (B) to remove 
unspecific noise, such as unfocused cell or cell debris. (C) The correlation between 
fluorescence lifetime and fluorescence intensity was shown in scatter plot; with 
each data point represented the information of one cell. (D) Diagram illustrated 
linear correlation between lifetime and brightness of donor fluorescence intensity.  
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 (2) Image acquisition  
The second category of error was with respect to image acquisition. It was found 
that the fluorescence intensity and shape of the cell could alter the lifetime of the 
sensor significantly, regardless of any biochemical treatment. These were taken into 
account during the analysis of the data. 
 
Measured fluorescence lifetimes were plotted alongside with donor fluorescence 
intensities in result figure 4.2.5A. It was evident that these two parameters were 
correlated when displayed as a scatter plot (4.2.5C), in which each data point 
represented the lifetime and fluorescence intensity measurement of an individual 
cell. The value was obtained by applying mask to cells using TRI2 software to get 
the image data only within the mask. Masking could also eliminate the noise levels 
which could be generated by unfocused cell, dying cell or cell debris (4.2.5B). The 
data showed the fluorescence brightness could affect lifetime measurement, cells 
with higher brightness had a lower measured fluorescence lifetime comparing to 
less bright cells. A greater reduction in fluorescence lifetime was also observed in 
round cells that were entering cell division, and those cells were usually the 
brightest (as illustrated in 4.2.5D). In addition, similar intensity-based fluorescence 
quenching effect was also found in another membrane-anchored Raichu-X probe, 
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Since this effect on fluorescence intensity can be a constant factor affecting lifetime 
measurement, false positive data could be generated by measuring cell populations 
with different fluorescence intensity instead of measuring its true response to the 
growth factor stimulation. For the siRNA screen, we avoided the brightest cell 
population that had the most lifetime quenching due to intermolecular FRET which 
was unrelated to EGFR activity. 
 
Furthermore, cell debris was avoided prior to data acquisition as we manually 
selected cells with phenotype that represented the normal cell population. Five 
view-fields per well were logged manually. The automated imaging system saved 
the marked x, y and z coordinates for each point. On completion of field of view 
marking, the system returned to each point and focussed using a high precision 
(auto-focus in 0.2µm lateral resolution) computer-controlled objective piezo 
mounting unit, then imaged consecutively for eGFP image and mRFP1 image. The 
system then switched automatically to laser-scanning mode to acquire the single 
photon data and save time-resolved images, continued in a high throughput fashion 
described in Material & Method section 3.15. 
  





   
Result figure 4.2.6: Associations between biosensor lifetime, fluorescence intensity 
and EGF stimulation.  
Fluorescence lifetime and intensity data for the HCC1954 cells transfected with the 
library of siRNA were imported into SPSS statistical software for correlation analysis. 
Pearson correlation coefficient (two-tailed) was reported for the association 
between intensity and Tau, statistical significant with P < 0.05. 
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(3) Data analysis 
In the next couple of sections, we analysed the intensity-based variation further 
and developed the statistical method to analyse the FRET-FLIM data. 
 
Once the FLIM data acquisition has been completed, the fluorescence lifetime was 
calculated by fitting mono-exponential fluorescence decay model.  The FLIM images 
obtained were batch analysed using in-house exponential fitting software (TRI2) 
written by Dr Paul Barber (Barber, Ameer-Beg et al. 2009). These files were then 
analysed to produce average lifetime data. We masked the fluorescence intensity 
image of each cell in parallel with its lifetime image, and exported the data to SPSS 
software to determine the association between donor GFP fluorescence lifetime, 
intensity, and EGF treatment. 
 
Large amount of cellular data was used for this analysis, cells were transfected with 
the siRNA library (with or without EGF treatment) (Result figure 4.2.6). Based on 
our pervious observation, we tested the hypothesis that there was a continuous 
variable (intensity) that was not part of the main experiment (EGF stimulation) but 
had an effect on the biosensor lifetime. Statistical data has confirmed this 
hypothesis. The Pearson correlation coefficient indicated a degree of correlation 
between fluorescence lifetime and intensity (= -0.171, p < 0.001), it showed that 
intensity had a constant influence on the lifetime value. 
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As expected, EGF also showed a significant effect on tau (t=7.53, p < 0.001), 
showing the response of the Picchu-X biosensor upon EGF receptor activation and 
underwent a change in intra-molecular folding, which promotes binding of SH2 
domain to phosphorylated Tyr221 and brings eGFP in close proximity to mRFP1, 
thereby triggering FRET. Furthermore, there was no association between intensity 
and EGF treatment (t=1.19, p=0.235), showing EGF had no effect on the brightness 
of the cells. 
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Linear regression line: 
 No EGF -0.051 
With EGF -0.141 





Linear regression line: 
 No EGF -0.034 
With EGF -0.102 




Linear regression line: 
 No EGF -0.017 
With EGF -0.089 




Linear regression line: 
 No EGF -0.054 
With EGF -0.177 
  P value for interaction: P=0.048 
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Linear regression line: 
 No EGF -0.011 
With EGF -0.069 





Linear regression line: 
 No EGF -0.011 
With EGF -0.066 




Linear regression line: 
 No EGF -0.036 
With EGF -0.150 




Linear regression line: 
 No EGF -0.048 
With EGF -0.119 
  P value for interaction: P=0.003 
 





Result figure 4.2.7: Picchu-X sensor response upon EGF stimulation for (A) non-
targeting siRNA and (B) library of siRNA classified not as hit. 
Tau distributions displayed as linear regression lines indicating Picchu-X sensor’s 
response upon EGF stimulation. Blue lines represented sensor lifetime after specific 
gene-knockdown, while red lines represented sensor lifetime after specific gene-
knockdown with EGF treatment. Linear regression models including an interaction 
term with EGF were performed using SPSS statistical software. The interaction term 
(between EGF and Tau, independently of the correlation between intensity and Tau) 
was statistically significant when p < 0.05. 
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Result (with control and non-hit examples) 
Previously we confirmed the associations between fluorescence intensity and 
lifetime, and for this reason, we cannot measure the effect of EGF stimulation 
based on the lifetime differences alone. A linear regression model was applied to 
observe the effect of EGF towards this association between intensity and Tau. 
 
To confirm the validity of our experimental approach, in Result figure 4.2.7, 
examples of the analysis for control scrambled non-targeting siRNA (4.2.7A) and 
‘non-hits’ from the siRNA library (4.2.7B) were shown. Maximum and minimum y-
axis values were set as 0.4ns apart (between 1.7 to 2.1ns or 1.8 to 2.2ns, depended 
on the time of acquisition/ decrease in lifetime, see Result figure 4.2.2). The 
parameters are described below: 
 
-Linear regression line 
Linear regression model, where Tau= slope*intensity + intercept (y= mx + c) was 
applied to observe the effect of EGF towards the association between intensity and 
Tau. An interaction term with EGF (dichotomous values, where EGF=0 or EGF=1) 
was included in the analysis, resulting in two linear equations of individual line. Blue 
lines represented sensor lifetime in cells after specific gene-knockdown; while red 
lines represented additional EGF stimulation. 
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In majority of samples, negative values were found (demonstrated as declining 




- P value for interaction 
The Pearson correlation coefficient analysis discussed previously in Result figure 
4.2.6 identified a linear association between intensity and Tau. The primary 
purpose of the linear regression model was to determine the effect of EGF 
stimulation toward this linear association. 
 
A T-test was reported for the association, if the p value was < 0.05 then there was a 
statistically significant interaction. When there was an interaction, the regression 
coefficient should have a low p-value of interaction, showing heterogeneity of 
regression lines, the gene was then classified as a ‘non-hit’; whereas if no 
interaction was presented, the lines would be approximately parallel with a high p-
value, those genes would be classified as ‘hit’.  











Result figure 4.2.8: Biosensor activity upon EGF treatment was calculated and 
possible hits were identified for further analysis. 
FLIM data was analysed using TRI2 software. Average tau data was extracted to 
calculate biosensor response to EGF stimulation after the knockdown of each 
specific gene. FRET efficiency correlated to lifetime measurement = 1- τ donor-
acceptor /τ donor. Genes coloured in BLUE indicated an increase in FRET efficiency 
after EGF treatment, hence classified as ‘non-hits’; while genes highlighted in RED 
colour were the possible hits, which shown no increase in FRET efficiency upon EGF 
treatment.  
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In addition to the primary screen with the pooled library, we repeated the 
experiment using a single siRNA sequence. In total we imaged twenty four 384-well-
plates in a dozen of individual experiments; each experiment acquired 980 images; 
whereas each image contained between three to six cells. Over 50,000 cells were 
imaged in total for the screen. Since we needed to use single cell data for 
comprehensive analysis, masking of cells was the most time-consuming, and yet 
important part of the analysis. Since it was impossible to individually mask and 
analyse each of the 50,000 cells for its fluorescence intensity and lifetime value, we 
designed preliminary test to eliminated non-hit samples, which responded to EGF 
treatment in similar manner as samples without non-targeted knockdown. 
 
Result figure 4.2.8 showed representative results from one of the experiments 
containing 88 siRNAs. Each blue bar showed increase in FRET efficiency due to EGF 
treatment and each red bar showed samples with abolished effect of EGF due to 
the absence of the targeted gene. Last five bars illustrated the effect of EGF in 
samples transfected with scrambled siRNA as control. Genes with an increase in 
FRET efficiency after EGF treatment were classified as ‘non-hit’ and would not be 
selected for further analysis; genes highlighted in red colour were further processed 
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Detailed analysis was required by applying masks to cells using TRI2 software for 
two purposes. First reason was to eliminate the noise levels which were generated 
by unfocused cell, dying cell or cell debris (as seen in Result figure 4.2.5B); secondly, 
to obtain individual fluorescence lifetime and intensity measurements in order to 
plot linear lines for regression coefficient analysis to identify genes that did not 
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Linear regression line: 
 No EGF -0.077 
With EGF -0.062 





Linear regression line: 
 No EGF -0.041 
With EGF -0.009 




Linear regression line: 
 No EGF -0.104 
With EGF -0.059 




Linear regression line: 
 No EGF -0.095 
With EGF -0.019 
  P value for interaction: p=0.007 
 












Linear regression line: 
 No EGF -0.076 
With EGF -0.071 





Linear regression line: 
 No EGF 0.120 
With EGF -0.002 




Linear regression line: 
 No EGF -0.041 
With EGF -0.035 




Linear regression line: 
 No EGF -0.069 
With EGF 0.019 
  P value for interaction: p=0.008 
 












Linear regression line: 
 No EGF -0.094 
With EGF -0.114 





Linear regression line: 
 No EGF -0.077 
With EGF -0.132 




Linear regression line: 
 No EGF -0.127 
With EGF -0.084 




Linear regression line: 
 No EGF -0.090 
With EGF -0.115 
  P value for interaction: p=0.566 
 












Linear regression line: 
 No EGF -0.098 
With EGF -0.081 





Linear regression line: 
 No EGF -0.093 
With EGF -0.030 




Linear regression line: 
 No EGF -0.101 
With EGF -0.083 




Linear regression line: 
 No EGF -0.054 
With EGF -0.078 
  P value for interaction: p=0.422 
 












Linear regression line: 
 No EGF -0.045 
With EGF -0.030 





Linear regression line: 
 No EGF -0.069 
With EGF -0.030 




Linear regression line: 
 No EGF -0.044 
With EGF -0.090 




Linear regression line: 
 No EGF -0.058 
With EGF -0.107 
  P value for interaction: p=0.357 
 







Result figure 4.2.9: siRNA classified as possible hits. 
Tau distributions displayed as linear regression lines 
indicating Picchu-X sensor’s response upon EGF 
stimulation. Blue lines represented sensor lifetime 
after specific gene-knockdown, while red lines 
represented sensor lifetime after specific gene-
knockdown with EGF treatment. Linear regression 
models including an interaction term with EGF were 
performed using SPSS statistical software. The EGF-
Tau interaction term was statistically significant 
when p<0.05. When p>0.05 or when the +EGF slope 
was less steep than the –EGF slope (in case of 






Linear regression line: 
 No EGF 0.010 
With EGF 0.013 





Linear regression line: 
 No EGF 0.034 
With EGF 0.031 
  P value for interaction: p=0.840 
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Result figure 4.2.10: List of the 22 candidate genes that modulate EGF-induced 
biosensor conformational changes identified in the siRNA library screen. 
Ref. Seq. 
Number 
Gene Brief description Reference 
NM_002673 PLXNB1 Transmembrane semaphorin receptor; 
coupling with c-MET 
(Giordano, Corso et al. 
2002) 
NM_016848 SHC3 Signalling adapter; interacts with 
activated EGFR. 
(Nakamura, Muraoka et 
al. 1998) 
NM_004946 DOCK2 Involves in the remodelling of actin 
cytoskeleton; binds to SH3 domain of Crk. 
(Nishihara, Maeda et al. 
2002) 
NM_002734 PRKAR1A Binds to Grb2 and allows PKA interaction 
with the activated EGFR. 
(Tortora, Damiano et al. 
1997) 
NM_001042589 C9orf127 Function unknown.  
NM_002834 PTPN11 Also known as SHP2; a protein tyrosine 
phosphatase for signal transduction. 
(Tomic, Greiser et al. 
1995) 
NM_015033 FNBP1 Interacts with CDC42; controls actin 
cytoskeleton. 
(Serebriiskii, Mitina et al. 
2002) 
NM_012116 CBLC E3 ubiquitin protein ligase C; interacts 
with EGFR and CrkII. 
(Keane, Ettenberg et al. 
1999) 
NM_013374 PDCD6IP Programmed cell death 6 interacting 
protein. 
(Schmidt, Dikic et al. 
2005) 
NM_000639 FASLG Interaction of FAS with this ligand is 
critical in triggering apoptosis. 
(Reinehr, Schliess et al. 
2003) 
NM_002389 CD46 Acts as co-stimulatory factor for T-cells. (Schneider-Schaulies, 
Dunster et al. 1995) 
NM_001469 XRCC6 DNA-dependent protein kinase; interacts 
with EGFR. 
(Bandyopadhyay, Mandal 
et al. 1998) 
NM_001033028 CYFIP1 Component of the WAVE1 complex; 
regulates actin filament reorganization. 
(Kobayashi, Kuroda et al. 
1998) 
NM_007176 C14orf1 Function unknown. (Stelzl, Worm et al. 2005) 
NM_152243 CDC42EP1 Rho GTPase; regulates actin 
polymerization. 
(Rual, Venkatesan et al. 
2005) 
NM_002309 LIF Interacts with IL6ST, which is a regulator 
of PTPN11 (SHP2). 
(Schiemann, Bartoe et al. 
1997) 
NM_001380 DOCK1 Downstream of Crk protein. (Gu, Sumida et al. 2001) 
NM_005369 MCF2 Modulates the Rho family of GTPases. (Zhu, Debreceni et al. 
2000) 
NM_007118 TRIO Interacts with Rac1 and Rho guanine 
nucleotide exchange factor. 
(Medley, Serra-Pages et 
al. 2000) 
NM_002166 ID2 Inhibitor of DNA binding. (Jogi, Persson et al. 2002) 
NM_001005743 NUMB Interacts with Notch1; plays a role in the 
process of neurogenesis. 
(McGill and McGlade 
2003) 
NM_005228 EGFR   
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Result (identified hits) 
To identify regulators of the EGFR signalling pathway, we performed a siRNA screen 
containing 533 genes. After 72hr of gene silencing using the library of siRNA, 
majority of the samples reacted to the EGF treatment, showing that these genes 
were not involved in the regulation of the receptor tyrosine kinase function of EGFR. 
In comparison, a minority of the genes might have knocked down an important 
regulatory component and abrogated the effect of growth factor (EGF) stimulation 
on the sensor conformation. Individual fluorescence lifetime and intensity 
measurements were used for regression coefficient analysis. We elevated the 
candidate genes by comparing homogeneity of the linear regression lines. The same 
parameters were previously described in Result figure 4.2.7. 
 
The scatter plots for all the candidate hits were showed in Result figure 4.2.9 along 
with the statistical analysis. In the initial screen using the independent siRNA pools, 
84 genes were identified as candidate hits; while 74 genes were indentified in the 
second screen using single siRNA sequence. Including EGFR, 22 genes overlapped 
between the two screens, which were 4.1% of the siRNA library.  
 
For the candidate hits, no interaction between the lines was presented. The lines 
were approximately parallel and had high p-values for interaction (for EGFR, p= 
0.676). 
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The siRNA screen had the potential to knock down an important signal transduction 
molecule or a crucial component of the signalling complex, led to delayed or lost of 
communication between EGFR and its downstream signalling targets. Result figure 
4.2.10 contained some information of the genes classified as potential hits, 
including the reference sequence number from the library and brief description on 
each gene with the corresponding reference. The reported activity could be 
directed to the communication between EGFR and CrkII protein, or reporting on 
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Result figure 4.2.11: Retention of EGFR and reduction of sensor activity after 
XRCC6 silencing. 
(A): HCC1954 cells were transfected with 10nM of non-targeting siRNA (siNT) or 
siRNA against XRCC6 for 72hr. Cell lyses were collected with or without further 
treatment of EGF (10ng/ml) for 30min. Immunoblots were carried out using the 
antibodies indicated above. (B) Western blot results were analysed with 
Quantity One software. Bar chart indicated phosphorylation level of CrkII, 
normalised to total expression of the respective protein.  
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After identified the background mechanisms that were published in the literature 
(see Chapter 5 discussion section), we decided to validate the role of three putative 
hits, XRCC6 (p=0.849), PDCD6IP (p=0.187) and PTPN11 (p=0.567). PDCD6IP and 
PTPN11 are the subject of investigation by Dr Ruhe Choudhury and Miss Appitha 
Arulappu, respectively, as part of their PhD doctorate studies. 
 
Effect of XRCC6 on EGFR signalling pathway and receptor degradation 
Binding of EGFR ligand can stimulate EGFR nuclear transport which was linked to 
gene transactivation (Friedmann, Caplin et al. 2004; Brand, Iida et al. 2011). Nuclear 
EGFR is localised on the nuclear membrane and in the nucleoplasm (Lo, Cao et al. 
2010). EGFR moves from the outer nuclear membrane to the inner nuclear 
membrane via interaction between importin β and the nuclear pore complex, 
whereas Sec61 interacts with EGFR and release the receptor from the inner nuclear 
membrane to the nucleus (Wang, Yamaguchi et al. 2010).  
 
Importantly, the level of nuclear EGFR correlates with poor prognosis in a variety of 
cancers, including breast carcinomas (Hadzisejdic, Mustac et al. 2010; Bau, Tsai et al. 
2011). Nuclear EGFR functions as a transcription cofactor that interacts with DNA-
binding transcription factors (such as STAT3 or Cyclin D1) and DNA dependent-
protein kinase (DNA-PK), which is required for repairing double strand DNA 
breakages (Friedmann, Caplin et al. 2006; Hsu, Miller et al. 2009; Liccardi, Hartley et 
al. 2011). 
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DNA-PK consists of heterodimeric regulatory complex XRCC5/XRCC6 (XRCC5 also 
known as ku80, while XRCC6 also known as ku70) and a large 460kDa catalytic 
subunit (Bandyopadhyay, Mandal et al. 1998; Collis, DeWeese et al. 2005; Martinez, 
Seveau et al. 2005). Although XRCC5 and XRCC6 are primarily found in nuclei, these 
proteins can also be found in the cytoplasm and at the plasma membrane 
(Prabhakar, Allaway et al. 1990; Koike 2002). Physical interaction between EGFR 
and XRCC5/XRCC6 was demonstrated in response to anti-EGFR monoclonal 
antibody treatment (Bandyopadhyay, Mandal et al. 1998) and in response to 
ionizing radiation, resulted in increased repair of DNA strand breaks (Liccardi, 
Hartley et al. 2011). 
 
To functionally characterise the regulatory role of XRCC6 on EGFR signalling, we 
measured its ability to modulate CrkII-based sensor activity in response to ligand 
stimulation through EGFR by immunoblotting. We confirmed the expression of 
XRCC6 in the HCC1954 basal-like breast cancer model and verified the knockdown 
efficiency of the XRCC6-targeting siRNA (Result figure 4.2.11, first row). With the 
silencing of XRCC6, two-fold decrease in the ligand-induced phosphorylation of the 
Picchu-X sensor (third row) was seen, in comparison to the control with non-
targeted knockdown using scrambled siRNA. 
 
A transient signalling complex composed of adaptor proteins and effectors is 
assembled following the activation of EGFR. For the regulation of signal output, this 
process is carefully coordinated by negative regulatory mechanisms by promoting 
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receptor internalization (mediated by clathrin), and subsequent ubiquitination and 
degradation of both ligand and receptor molecules by ubiquitin ligase Casitas B-
lymphoma (Cbl). The receptor can also undergo recycling to the plasma membrane 
(Yarden 2001; Dikic and Giordano 2003; Lemmon and Schlessinger 2010; Avraham 
and Yarden 2011). XRCC6 knockdown demonstrated an impaired intracellular 
degradation of the receptor (second row), suggesting that XRCC6 might interfere 
with normal EGFR signalling pathway and diminish receptor degradation. 
 
Knowledge of such genes will advance our understanding the role of nuclear EGFR 
in basal-like breast cancer, and help clarify some of the molecular mechanisms 









In summary, we reported for the first time an integrated high-content high-
throughput workflow that combined two powerful methods of cell biology and 
molecular imaging: siRNA screening and FLIM imaging using intra-molecular FRET-
based biosensor. 
 
These protein activity sensing/imaging techniques allowed us to interrogate an 
EGFR-centric subnetwork of proteins consist of 533 genes interconnected with 
EGFR directly or indirectly. We identified 22 candidate genes that have a potential 
in regulation of EGFR signalling pathway in basal-like breast cancer cells. 
 
The screen increased our knowledge about molecular factors that may influence 
the therapeutic sensitivity of the EGFR network and might be translated to 
potential prognostic or predictive biomarkers for better understanding of tumour 
cell sensitivity to EGFR inhibition and may thereby suggest new combination 
treatments. 
  







4.3: Liposomal transfection of Picchu-X sensor to 
measure intratumoural EGFR activity 
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Chapter introduction - Liposomal transfection of Picchu-X sensor to measure 
intratumoural EGFR activity 
 
In previous chapters, we studied the dynamics of EGFR activity in a variety of cells 
lines and its modulation by known EGFR inhibitors using the modified FRET-based 
sensor (Picchu-X), providing the basis for the next phase of the project, which was 
to develop multifunctional EGFR-targeted liposome and to address the liposomal 
potential on intratumoural activity sensing in murine models of basal-like breast 
cancer. This part of the project was cooperated with Professor Alethea Tabor’s 
laboratory, with the synthesis of liposome was carried out by Dr Nick Mitchell at 
University College London, while all cell-based and animal works were done in 
Professor Tony Ng’s laboratory at King’s College London. 
 
We presented here a cellular and in vivo delivery system that was based on these 
nanoliposomes. These multifunctional liposomes were conjugated with EGFR-
targeting peptides for the delivery of biosensor-encoding DNA. Once the 
transfection conditions were optimised in the cellular system, we applied the 
liposomes intravenously into established xenograft models of basal-like breast 
cancer. This approach allowed us to study the dynamics of EGFR activity in the 
primary tumours and demonstrated a significant degree of intratumoural 
heterogeneity in EGFR activity, as well as its modulation by EGFR tyrosine kinase 
inhibitor, Morpholino-IPQA. 
  







Result figure 4.3.1: Confocal fluorescence study of liposomal transfected HCC1954 
cells. 
Confocal fluorescence images demonstrated the expression of membrane-bound 
Picchu-X sensor (green and red) in liposomal transfected HCC1954 cells. Liposome 
contained 5% Cy5-labelled lipid (yellow) and nuclei was stained with Hochst33342 
(Blue), white scale bar represents 20µm. 
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We aimed to develop a lipid-based nanoparticles delivery system to formulate 
serum-stable liposomes for effective delivery of the FRET-based sensor to study the 
dynamics of EGFR activity in murine model of basal-like breast cancer. 
  
Liposomal transfection of Picchu-X sensor 
Cellular experiments were performed to check liposomal transfection efficiency. 
We found that most transfection events took place in the first few hours of the 
incubation period within the culture wells. High concentration of liposome solution 
(> 50µM) together with longer length of incubation (longer than 4 hours) was 
shown to cause cytotoxicity to most cells.  The optimum liposome concentration 
was established to be 10µM and the damage was much less severe even without 
washing away the unbound liposome after the initial 4-hour incubation period. Cells 
were left in incubator for further 48 hours to allow the expression of Picchu-X 
sensor protein. 
 
Confocal fluorescence microscopy studies of the intracellular fate of liposome lipid 
and the transfected sensor was shown in Result figure 4.3.1. We observed the 
membrane expression of Picchu-X sensor (green for eGFP and red for mRFP1) in 
some of the HCC1954 cells and various amount of Cy5-labelled lipid intake (yellow) 
was either distributed throughout the cytoplasm or confined to endocytic vesicles 
distributed in almost all cells.  This observation showed that Cy5-labelled lipid 
intake was not an indicator for DNA plasmid transfection as the sensor did not 
necessary expressed in all the cells that were transfected with liposome. 























Result figure 4.3.2: Selection of targeting peptides for the enhancement of 
liposomal uptake and DNA transfection. 
Liposomes were modified with a panel of targeting peptides to enhance liposomal 
uptake in MDA-MB-231 cells. Epifluorescence intensity was scanned using motorized 
microscope system. ImageJ software was used for the analysis of normalised-pixel 
count (Cy5/UV for liposomal uptake and GFP/UV for DNA transfection). All complexes 
were prepared at 4:1 weight ratio of lipid to DNA. 
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Selection of targeting peptides to enhance liposomal uptake and DNA 
transfection 
Further optimization steps were done to strengthen the efficiency and specificity of 
liposomal transfection. Result figure 4.3.2 has shown that the small structural 
difference in the selection of peptide sequence for receptor targeting could result 
in pronounced differences in liposomal uptake and DNA transfection. 
 
All liposomes contained PEG-shielding polymer in additional to DOTMA, DOPE and 
30% cholesterol, which were the constituent lipids used in all formulations. We 
used bifunctional targeting peptide designed to both condense the DNA through 
the K16 (lysine-rich) region, and to facilitate EGFR specific receptor-mediated 
transfection. Pervious in vitro transfection studies revealed that ternary 
formulations of lipid:peptide:DNA (LPD) complexes possessed higher transfection 
activity compared to their respective lipid:DNA (LD) counterparts (Kudsiova, Fridrich 
et al. 2011). It has been recognised that the installation of targeting peptides could 
lead to more efficient internalization via receptor-mediated endocytosis and 
consequently higher transfection efficiency (Mustapa, Bell et al. 2007; Kudsiova, 
Fridrich et al. 2011). All complexes were prepared at 4:1 weight ratio of lipid to DNA. 
 
MDA-MB-231 cells were incubated with Cy5-labelled liposome carrying no targeting 
peptide (K16 alone), or with purified EGFR-targeting peptide LARLLT, YHWYYPQNVI, 
or synthetic fragment of EGF CAYKDLAEIYM (Park and Yoo 2010). These peptides 
passed through the lipid bilayer and were exposed on the exterior surface of the 
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liposome complex. These peptides were connected to K16 by an enzymatically 
cleavable linker sequence RVRR, which was recognised by the endosomal proteases 
cathepsin B and furin, to allow removal of the PEG moiety and detachment of the 
nanocomplex from the receptor (Mustapa, Grosse et al. 2009; Grosse, Tagalakis et 
al. 2010).  
 
Fluorescence emission signal was scanned using motorised microscope system 
described in Material & Method section 3.15. Signal for Picchu-X sensor was 
scanned in Cy2 channel (eGFP), signal for lipid intake was scanned in Cy5 channel 
(Cy-5 labelled lipid) and nuclei signal was scanned in UV channel (Hoechst33342). 
ImageJ software was used for the analysis of normalised-pixel count. Liposome 
uptake ratio was calculated by Cy5/UV, while sensor expression was calculated by 
GFP/UV.  
 
As shown in Result figure 4.3.2, sensor expression were found in cells that were 
applied with liposome carrying no targeting peptide (K16 alone), indicating that 
DNA can be transfected by unspecific passive uptake through electrostatic 
interactions inside the cell culture system.  
 
A 4.7-fold increase of liposomal uptake was observed with the addition of 
YHWYYPQNVI comparing to K16 control (p < 0.05), but with significantly lower 
expression of sensor protein (12.7-fold decrease, p < 0.01). This might be due to the 
poor endosomal release of the liposome or enzymatic degradation of the DNA in 
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the endosomal/lysosomal compartment (Kudsiova, Fridrich et al. 2011). In contrast, 
the presence of peptide sequences LARLLT and CAYKDLAEIYM showed 
enhancements in both liposomal uptake and transfection of sensor DNA comparing 
to K16 control without receptor targeting. 
  






Result figure 4.3.3: Picchu-X sensor expression in xenograft model of MDA-MB-231 
basal-like breast cancer. 
Representative lifetime and fluorescence images of in vivo liposomal transfection of 
Picchu-X sensor-encoding DNA into primary tumour of MDA-MB-231 xenograft 
model of basal-like breast cancer. Nuclei were stained with Hoechst33342, white 
scale bar represents 10µm. 
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The major goal for this part of the project was the generation of multifunctional 
liposomes, which are loaded with lipids that carry EGFR-target peptide for cell 
recognition, small molecule inhibitor for inhibiting EGFR kinase activity, and DNA 
encoding FRET-based biosensor for measuring EGFR kinase activity. 
 
In vivo liposomal delivery of Picchu-X sensor 
After the optimization of the LPD formulation in the cellular system, we tested the 
liposomal delivery method in vivo using the highly metastatic MDA-MB-231 basal-
like breast cancer model. We included the CAYKDLAEIYM peptide sequence in the 
liposome formulation for the selective targeting of EGFR due to the enhancements 
in liposomal uptake (2.8-fold increase, p < 0.01) and transfection of sensor DNA 
(1.6-fold increase, p < 0.04) compared to K16 control without receptor targeting in 
the cellular system (see Result figure 4.3.2). 
 
The liposome injection was performed three weeks after subcutaneously injection 
of cancer cells into four-week-old female Crl:CD1-Foxn1 nu/nu mice. The liposome 
solution was injected through tail vein into the animal and was allowed 48 hours for 
the Picchu-X sensor protein maturation. The liposome solution was also applied on 
monolayer of cultured cell to confirm the transfection efficiency of the batch used 
for tail vein injection. Solid primary tumours were dissected out and snap-frozen in 
liquid nitrogen. Frozen tumours were cut into 4µm sections with a cryostat for 
time-resolved multi-photon-FLIM imaging experiments. 
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As shown in Result figure 4.3.3, membrane expression of Picchu-X biosensor was 
observed in the primary tumour samples, with the eGFP and mRFP1 fluorescence 
signals associated with individual nucleus of the transfected cell. We measured an 
average lifetime of 1.795ns for MDA-MB-231 model; the lifetime value was 
comparable with the in vitro imaging data.  



































Pearson correlation coefficient = 0.545 (p = 0.024)  
Result figure 4.3.4: Intratumoural heterogeneity of EGFR activity and the 
correlation between Picchu-X sensor activities with the distance to blood vessels 
within the tumour environment. 
(A) Heterogeneity of Picchu-X activity in tumour environment of MDA-MB-231 
model; white scale bar represents 5µm (B) Schematic model showing the co-
migration of tumour cells and macrophages on collagen fibres and their 
intravasation into blood vessels within the tumour microenvironment of metastasis 
(TMEM). (C) MDA-MB-231-bearing animals were injected with LPD complex 
containing 68µg of Picchu-X sensor DNA. Ex-vivo tissue samples were stained with 
Alexa-Fluor-647 anti-mouse CD31 antibody to correlate Picchu-X sensor (shown in 
GFP) distance to blood vessels (shown in Alexa-Fluor-647). Nuclei were stained with 
Hochst33342 (shown in UV); white scale bar represents 10µm. (D) Correlation 
between Picchu-X sensor activities to distance to blood vessels. Data was imported 
into SPSS statistical software for correlation analysis. Statistical significant (with P < 
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Heterogeneity of EGFR activity within the tumour microenvironment 
Heterogeneity of EGFR activity was demonstrated by the FRET-based sensor within 
the tumour environment in the MDA-MB-231 basal-like breast cancer model 
(Result figure 4.3.4A); we tested the hypothesis that EGFR activity was correlated 
with the distance to blood vessel or to macrophage within the tumour 
microenvironment of metastasis (TMEM). 
 
Robinson et al. have shown that density of TMEM correlates with the risk of 
developing systemic, haematogenous metastases in breast cancer (Robinson and 
Jones 2009; Robinson, Sica et al. 2009). As illustrated in Result figure 4.3.4B, TMEM 
is defined as a tripartite arrangement of a tumour cell, a macrophage and an 
endothelial cell. This tumour microenvironment invasion model suggests that 
tumour cells and macrophages participate in a paracrine loop involving 
macrophage-derived EGF and carcinoma cell-derived colony-stimulating factor-1 
(CSF-1), results in tumour cell migration along collagen fibres and intravasation, 
with the assistance of perivascular macrophage (Condeelis and Pollard 2006; 
Pollard 2008; Qian and Pollard 2010).  This cross-talk can be blocked by either EGF 
or CSF-1 receptor antagonists, resulting in a decrease in migration and invasion of 
both tumour cells and macrophages (Goswami, Sahai et al. 2005). 
 
By liposomal delivery of the FRET-based sensor, we measured the intratumoural 
EGFR activity in related to the distance to blood vessels and macrophages in ex-vivo 
MDA-MB-231 tissue samples.  
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Tumour-bearing animals were injected with LPD complex containing 68µg of 
Picchu-X sensor DNA. This liposome solution was also tested in cultured cell in 
parallel to confirm the transfection efficient of the batch.  
 
Primary tumours were dissected out 48hr post-injection and sectioned on imaging 
slides for immunostaining experiments. We stained and visualised blood vessels 
using Alexa-Fluor-647-conjugated CD-31 antibody (as shown in Result figure 4.3.4C). 
The result showed a correlation between the sensor activities and distance to blood 
vessels (Pearson correlation coefficient = 0.545, p = 0.024), whereas the EGF-
receptors were more active when cells were near the blood vessels (Result figure 
4.3.4D). 
 
Tumour-associated macrophages populate the tumour microenvironment and 
constitute a large portion of the tumour mass, particularly in breast cancers (Lewis 
and Pollard 2006). We stained the macrophages with F4/80 antibody and measured 
the sensor activity correlated to the distance to the nearest macrophage. No 
significant association was seen between EGFR activity and the proximity of the 
tumour cells to macrophages (Pearson correlation coefficient = 0.069, p = 0.830). 
These results (inverse correlation of EGFR activity in tumour cells with their 
distance from blood vessels) are being further explored mechanistically in the 
supervisor’s laboratory; for instance in relation to redox regulation of EGFR activity 
(Paulsen, Truong et al. 2012; Truong and Carroll 2012). 
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Moreover, the expression of the sensor was poor in the model, usually only a few 
transfected cells were found in each tumour section. Multiple tumour sections 
were required to obtain data for statistical significance. Spleen and liver samples 
were also imaged but the expression of sensor protein was hardly observed. 
  















Result figure 4.3.5: Selection of cell-line and optimization of LPD formulation for 
the enhancement of liposomal uptake and DNA transfection. 
(A) In vitro liposomal uptake (Cy5 scan) and biosensor expression (GFP scan) were 
compared between HCC1954 and MDA-MB-231 models with a panel of targeting 
peptides. (B) ImageJ software was used for the analysis of normalised-pixel count 
(Cy5/UV for liposomal uptake and GFP/UV for DNA transfection) for the HCC1954 
model, while all complexes were prepared at 4:1 weight ratio of lipid to DNA. (C) 
Liposome complexes containing purified EGFR targeting peptide YHWYYPQNVI were 
prepared at 4:1 or 2:1 lipid:DNA ratio and demonstrated an enhanced level of DNA 
transfection with the lowered peptide ratio. Data were expressed as means ± SEM, 
statistical significance compared with K16 control was analysed using unpaired two-
tailed Student’s t-test. 
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Cell-line selection and in vitro optimisation of LPD formulation 
After the initial set of in vivo liposomal delivery experiments for the biosensor DNA, 
we observed low expression of sensor expression in the MDA-MB-231 tumours. 
Further optimization steps were done in attempt to improve the transfection 
efficiency. First, it was demonstrated that HCC1954 model had a better transfection 
capability in vitro, both in liposomal uptake and expression of the sensor protein, 
compared to the MDA-MB-231 model (Result figure 4.3.5A).  
 
We further analysed the scanned image of HC1954 cells transfected with liposomes 
attached with a panel of targeting peptides, which included purified EGFR-targeting 
peptide YHWYYPQNVI (Result figure 4.3.5B sample 2), LARLLT (sample 3), or 
synthetic fragment of EGF CAYKDLAEIYM (sample 6) (as referred to the same set of 
sequences used in Result figure 4.3.2 for the MDA-MB-231 model). Here, we also 
included two new samples of YHWYYPQNVI and LARLLT sequences that were 
attached to K16RVRR linkers in a reverse direction (sample 4 and 5 respectively), to 
check if the orientation of peptides passing through the lipid bilayer would affect 
their targeting abilities.  
 
Result showed a 2.8-fold increase in liposomal uptake (P < 0.02) and 1.4-fold 
increase in sensor expression (p < 0.03) with the addition of CAYKDLAEIYM peptide 
sequence compared to K16 control (Result 4.3.5B, sample 6). Data was highly 
comparable with previous result obtained using the MDA-MB-231 cells. It was also 
demonstrated a 4.7-fold increase of liposomal uptake (p < 0.05) with the addition of 
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YHWYYPQNVI sequence comparing to K16 control, but once again a significantly 
reduction in the expression of sensor protein (11-fold decrease, p < 0.01) (sample 2) 
as shown in the MDA-MB-231 cells previously. The attachment of peptides to 
K16RVRR linkers in a reverse orientation did not enhance liposomal uptake or 
sensor expression (sample 4 and 5). 
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Optimisation of LPD formulation for in vivo targeting 
For in vitro experiments, we would expect a degree of unspecific liposomal intake 
as the liposome solution was incubated directly on top of the monolayer of cell in 
the culture wells. However, with the consideration that once the liposome was 
injected into xenograft animal model, the lipid-based nanoparticle would need to 
circulate around the vascular system in order to locate and target the EGFR-
overexpressed cancer cells; thus it would be ideal to select a liposome formulation 
that produce the highest targeting efficiency. 
 
The addition of peptide sequence YHWYYPQNVI led to the highest degree of 
liposomal uptake among all the EGFR-targeting peptides tested. To solve the 
problem of its low transfection of DNA, we adjusted the weight ratio of lipid to DNA 
in attend to increase the release of DNA. Result figure 4.3.5C showed that an 
enhanced level of DNA release/sensor expression with the lowered 2:1 ratio 
comparing to the original 4:1 ratio, while the liposome intake remained highly 
superior. 
 
This result suggested that the reduction in transfection efficiency was most likely a 
consequence of poor endosomal release of DNA due to the formation of multiple 
bilayers surrounding the central core. It was important to have enough lipids to 
form a single bilayer on the exterior of the LPD complex but not so much that 
multiple bilayers are formed. This LPD formulation conjugated with peptide 
sequence YHWYYPQNVI, with 2:1 weight ratio of lipid to DNA, was selected for the 
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delivery of biosensor-encoding DNA into the xenograft HCC1954 model of basal-like 
breast cancer. We measured an average lifetime of 1.815ns in HCC1954 model, 
compared to 1.795ns for MDA-MB-231 model; both of these lifetime values were 
comparable with the in vitro imaging data. 
 
Results indicated that optimization steps can be done to strengthen the efficiency 
and specificity of liposomal transfection by adjusting the chemical formulations and 
surface properties of the liposomes. Small structural difference in the selection of 
targeting peptide for receptor recognition or lipid to DNA ratio could result in 
pronounced differences in transfection within each type of formulation. 
 
  















Result figure 4.3.6: Morpholino-IPQA inhibited Picchu-X sensor activity in HCC1954 
xenograft model. 
HCC1954-bearing animals were injected with LPD complex containing 68µg of 
Picchu-X sensor DNA. After 48hr, Morpholino-IPQA (MO-IPQA) was suspended in 
sterile and filtered water at pH 6.5 (at 10mg/ml) and 100ul was delivered 
intravenously to the mice (32mg/kg). Primary tumours were dissected out 4hr post-
treatment of the inhibitor. Picchu-X sensor activity was measured with MP-FLIM 
using the ex-vivo tissue samples. (A) Lifetime and (B) FRET efficiency data were 
expressed as means ± SEM and in statistical significance was analysed using unpaired 
two-tailed Student’s t-test.  
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Morpholino-IPQA inhibition of intratumoural Picchu-X sensor activity 
We have previously investigated inhibitory effects of Morpholino-IPQA (Gelovani 
2008) and its precursor PD168393 (Fry, Bridges et al. 1998) on EGFR activity in 
cultured cells (Result figure 4.1.1). Here we tested the inhibition of EGFR tyrosine 
kinase activity measured by liposomal delivery of the FRET-based sensor in the ex-
vivo HCC1954 tissue samples. 
 
Ten tumour-bearing animals were injected with LPD complex containing 68µg of 
Picchu-X sensor DNA. After 48hr, Morpholino-IPQA was suspended in sterile and 
filtered water at pH 6.5 (at 10mg/ml) and 100ul was delivered intravenously to the 
five mice (32mg/kg). Primary tumours were dissected out 4hr post-treatment of the 
inhibitor and sectioned on imaging slides for MP-FLIM imaging experiments.  
 
Result figure 4.3.6A showed a change in sensor lifetime from average tau of 
1.830ns, increased to 1.897ns compared with post-injection of Morpholino-IPQA 
(TTEST, p < 0.005); the data also demonstrated a 3% decrease in FRET efficiency 
(TTEST, p < 0.005). This indicated a conformational change of the CrkII-based sensor 





























   
Result figure 4.3.7: EGFR-targeted nanoparticles for the delivery of Morpholino-
IPQA. 
(A) HCC1954 cells were treated with 10µM of Morpholino-IPQA (Mo-IPQA) for 0, 4, 
24 and 48hr (without refreshing the inhibitors). One of each replicated well was 
treated with 100ng/ml EGF for 30min, prior to lysis. (B) HCC1954 cells were tested 
with (1) (2) untreated (3) Morpholino-IPQA; or tested with a panel of liposome 
complexes containing purified EGFR targeting peptide YHWYYPQNVI for 4hr, in 
addition to (4) sensor DNA (5) Morpholino-IPQA (6) sensor DNA and Morpholino-
IPQA. Except the control untreated well, all samples were treated with 100ng/ml 
EGF for 30min, prior to lysis. Immunoblots were carried out using the antibodies 
indicated above. 
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EGFR-targeted nanoparticles for the delivery of EGFR tyrosine kinase inhibitor  
Previously we have shown the result of monitoring EGFR activity in the tumour 
microenvironment in response to the given drug treatment. In order to create a 
nanoparticle delivery system that can carry both inhibitor and sensor-encoding DNA, 
we further tested the duration of EGFR kinase inhibition of Morpholino-IPQA to 
check if the effect would last for the time required for sensor protein maturation. 
 
Result figure 4.3.7A showed the inhibitory effect of Morpholino-IPQA remained for 
at least 48hr in cultured cells, without the need of refreshing or additional doses of 
inhibitors; thus for in vivo experiments, only one initial injection of the LPD-drug 
complexes would be required. However, the production of such LPD-drug complex 
has been proven to be difficult and unsuccessful.  
 
As shown in Result figure 4.3.7B, we tested three LP formulations that contained 
either (B4) sensor DNA (B5) Morpholino-IPQA or (B6) sensor DNA with Morpholino-
IPQA; each LP complex contained EGFR targeting peptide YHWYYPQNVI. All 
liposome solutions were then purified in PD-10 columns in order to remove 
unencapsulated compounds.  
 
The results showed that Morpholino-IPQA was successfully encapsulated in the 
liposome and released from the LP complexes to inhibit EGFR kinase activity in the 
cultured cells (as shown in B5). However, no inhibition was seen with the addition 
of sensor DNA (as shown in B6), indicating the absence of the inhibitor. This 
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suggested that when forming a complex with DNA, a profound structural 
rearrangement of the outer liposomal surface had forced all the inhibitors to be 
released from the LP complexes. 
  





In summary, we have demonstrated in vivo liposomal transfection of Picchu-X 
biosensor into HCC1954 and MDA-MB-231 tumour tissues. We were able to 
measure EGFR activity in the micro-environment in those tumours in response to 
the given drug treatment. Furthermore, heterogeneity of biosensor activity was 
demonstrated within tumour environment and we found an inverse correlation of 
biosensor activity with distance from the tumour cells to blood vessel (CD-31 
antibody). 
 
This work highlights the advantages of liposomal delivery of biosensor to monitor 















CHAPTER 5: Discussion and future direction 
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Discussion and future direction 
 
Combinations of new and existing techniques were used in this project to 
investigate and to obtain a more comprehensive picture of the EGFR signalling 
processes. Here we reported for the first time an integrated high-content high-
throughput workflow that combined two powerful methods of cell biology and 
molecular imaging: siRNA screening and FLIM imaging using intramolecular FRET-
based biosensor (Picchu-X). The first objective of this work was to use an in-house 
developed semi-automated imaging technique to conduct a high-content high-
throughput FLIM screen, in combination with RNAi-based knockdown technique 
utilising a library of siRNA consisted of 533 genes, that were selected on the basis of 
the EGFR interaction subnetwork information, as explained in a previous section 
(Introduction chapter 1.10 Optical imaging for network screen).  
 
The second objective of this work was to develop a liposome-based delivery system 
to deliver the same biosensor into murine models of basal-like breast cancer for the 
measurement of intratumoural EGFR activity, as well as the effect of EGFR 
inhibitors in vivo. 
 
High-content screen using Picchu-X biosensor 
We characterised the CrkII-based biosensor in the cellular systems of basal-like 
breast cancer in Result chapter 4.1. By monitoring the sensor conformation 
changes with FRET-FLIM imaging, we could indirectly detect the changes in EGFR 
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activity to biological/therapeutics perturbations in situ, such as stimulation upon 
ligand binding and inhibition with small molecule inhibitors. 
 
The Picchu-X sensor was then selected to be employed in the large scale siRNA 
screen against a protein network consisted of 533 genes interconnected with EGFR 
directly or indirectly (up to second degree of interaction), that were chosen from 
the Human Protein Reference Database. As anticipated, the development of this 
large-scale protein activity screen require careful planning, followed by 
reconstructing and standardising the experimental layout, as shown in Result 
chapter 4.2, to generate result in a consistent and meaningful way throughout the 
whole screening process. 
 
After careful masking analysis of the acquired images, it was found that the 
fluorescence intensity could alter the lifetime of the sensor significantly, regardless 
of any biochemical treatment. To avoid false positive data, this intensity-based 
fluorescence quenching effect was taken into account during the analysis of the 
data. One plausible explanation that this was caused by the high concentration of 
sensor protein on cell membrane and led to intermolecular (rather than 
intramolecular) FRET with the increased number of neighbouring acceptor 
molecules. 
 
In addition to the overexpression that could lead to sensor multimerisation, the 
sensor was trapped on the cell membrane. The membrane targeting CAAX 
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sequence of k-RAS was cloned after the eGFP as a plasma membrane-anchoring 
motif to overcome the flaw that the diffusion of Picchu probe was too fast to 
delineate the sub-cellular localization of tyrosine kinase activity (Itoh, Kurokawa et 
al. 2005). The local concentration of the sensor could be very high and could be 
considered as a two dimensional problem, governed by the number of molecules 
within the area determined by the Förster radius (Lakowicz 1999). This idea 
supported our observation of inverse relationship between the fluorescence 
intensity and the fluorescence lifetime was due to the presence of multiple 
(intramolecular and intermolecular) acceptors for the donor molecule.  
 
This might also explain the slightly limited dynamic range we observed with the 
intra-molecular FRET-based sensor. In theory, there were two populations of 
sensors which were active (in closed confirmation) or inactive (open confirmation); 
these populations under the additional condition that the membrane was crowded 
enough to cause intermolecular FRET. However since the lifetime of the sensor 
would be further reduced after EGF stimulation by intramolecular energy transfer, 
we expected to find a change in the gradient of the lifetime versus intensity curve. 
 
We described the statistical analysis method to interpret the FRET-FLIM data 
generated, taken into account that there was an association between fluorescence 
intensity and lifetime. We therefore applied a linear regression model, where Tau= 
slope*intensity + intercept, to observe the effect of EGF towards the linear 
association between intensity and lifetime for ‘hit’ selection, with an interaction 
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term of EGF (dichotomous values, where EGF=0 or EGF=1) included in the analysis, 
resulting in two linear equations describing the ± EGF sample sets.  
 
Overview of genes identified as candidate hits 
FRET imaging microscopy has been proven to be an extremely useful tool in the 
detection of protein-protein interactions and protein conformational changes in 
single-cell level and provides temporal and spatial information on the molecular 
events. The siRNA screen described in Result chapter 4.2 had the potential to knock 
down an important signal transduction molecule or a crucial component of the 
signalling complex, leading to a potentially delay or loss of signal propagation from 
EGFR to its downstream signalling targets. We designed the screen to specifically 
report on the activity of EGFR rather than other RTKs such as c-Met and PDGFRβ 
(that can also phosphorylate the CrkII-based sensor probe; see section 4.1 
summary). This receptor specificity is introduced into the screen by defining the hits 
to be siRNAs that abrogate the difference between the ± EGF slopes of the linear 
equation (Tau= slope*intensity + intercept). Below, we discussed the 22 target 
genes (4.1% of the siRNA library) that were identified as modulators of EGFR 
activity response to its natural ligand. 
 
Hit proteins that interact with CrkII protein 
Three of the candidates have been showed to interact with CrkII protein directly. 
DOCK1 is a guanine nucleotide exchange factor for Rac, it has been shown to couple 
with p130Cas and CrkII to form a complex to serve as a molecular switch, regulating 
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integrin-mediated cell migration through enhanced lamellipodia formation (Gu, 
Sumida et al. 2001); while DOCK2 has been showed to complex with CrkII and Vav 
to regulate Rac activity on cell motility (Nishihara, Maeda et al. 2002). CBLC is a 
RING finger type ubiquitin-protein isopeptide (E3) ligase that interacts with EGFR 
and is involved in its ubiquitination and downregulation of its downstream 
signalling (Courbard, Fiore et al. 2002). It interacts with the SH3 domain of CrkII 
protein (Keane, Ettenberg et al. 1999). There were also reports on Crk involvement 
in the signalling of T cells and B cells by means of binding to CBLC. (Buday, Khwaja 
et al. 1996; Ingham, Krebs et al. 1996; Keane, Ettenberg et al. 1999). 
 
Hit proteins that associate with EGFR 
A number of the hit proteins have been reported to directly associate with EGFR. 
SHC3 (N-SHC) is an adapter molecule downstream of EGFR, and forms a complex 
with Grb2 following EGF stimulation (Nakamura, Sanokawa et al. 1996; Nakamura, 
Muraoka et al. 1998). PRKAR1A is a type I protein kinase A isoform, its regulatory 
subunit R1α is overexpressed in cancer cells and is induced by EGFR-dependent 
transformation (Tortora, Damiano et al. 1997). It has been shown that the 
downregulation of PRKAR1A inhibited EGFR dependent signalling by binding to the 
SH3 domain of Grb2 adaptor protein (Tortora, Damiano et al. 1997). PTPN11 
belongs to the family of protein tyrosine phosphatases (PTP) that can be 
categorised as receptor-like (R) or non-transmembrane (N) proteins (Tonks 2006). 
PTPN11 encodes for the SH2 domain-containing protein tyrosine phosphatase-2 
(SHP2), which contained two SH2 domains that partner with Grb2-associated binder 
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1/2 (GAB1/2). The interaction is essential for the activation of the Ras-Erk cascade 
downstream to EGFR (Tomic, Greiser et al. 1995; Cunnick, Dorsey et al. 2000; 
Fragale, Tartaglia et al. 2004). In a PTPN11-dependent manner, GAB2 
overexpression has been linked to breast carcinogenesis (Bentires-Alj, Gil et al. 
2006; Brummer, Schramek et al. 2006). In addition, PTPN11 showed an enrichment 
in the activated EGFR-Shc-associated cell fraction after EGF stimulation (Blagoev, 
Kratchmarova et al. 2003). XRCC6 (also known as Ku70) forms heterodimeric 
regulatory complex with ku80 and DNA-dependent protein kinase (DNA-PK) and 
plays an essential role in repairing DNA damage. A specific physical interaction 
between EGFR and Ku70/80 was demonstrated in response to anti-EGFR 
monoclonal antibody (mAb 225) treatment (Bandyopadhyay, Mandal et al. 1998). 
Enhanced EGFR nuclear localisation was induced by DNA damage-inducing agents 
and played a role in the modulation of DNA repair activity (Hsu, Miller et al. 2009; 
Liccardi, Hartley et al. 2011). Our result also demonstrated that XRCC6 knockdown 
led to a reduction of ligand-induced EGFR degradation, which was compatible with 
a reduced level of receptor phosphorylation (Result figure 4.2.11). 
 
PDCD6IP (also known as Alix) is an Endosomal Sorting Complexes Required for 
Transport (ESCRT)-Associated Protein, that has been shown to bind to EGFR 
constitutively and negatively regulate receptor internalization by reducing the 
phosphorylation levels of c-Cbl, weakening the interaction between SETA/CIN85 
and Cbl. These result in a reduction in Cbl-mediated degradation of EGFR (Schmidt, 
Hoeller et al. 2004; Schmidt, Dikic et al. 2005). FASLG is the natural ligand for FAS 
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receptor (also known as CD95). Death-inducing signalling complex (DISC) is formed 
upon ligand binding and initiate apoptosis. It was shown that oxidative stress can 
trigger the association between CD95 and EGFR (Reinehr, Schliess et al. 2003); 
while the interaction of FAS receptor and c-MET was shown to inhibit self-
association of FAS receptors and DISC formation, and cause resistance to FAS-
mediated apoptosis in endothelial cells (Smyth and Brady 2005). 
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Hit proteins with indirect relationship to EGFR or CrkII 
Plexin B1 (PLXNB1) is a transmembrane semaphorin receptor which shares 
homology to the extracellular domain of hepatocyte growth factor receptor, c-MET 
(Giordano, Corso et al. 2002). It has been shown to the knockdown of PLXNB1 
suppresses c-MET and HER2 activation through direct receptor-receptor interaction 
and decreases c-MET downstream effects by downregulating the activity of Shp2, 
which is a downstream adaptor protein for multiple receptors (Swiercz, Worzfeld et 
al. 2008; Soong and Scott 2013). The relationship between Leukemia inhibitory 
factor (LIF) and EGFR is unknown; however an interaction was suggested between 
LIF and IL6ST (Interleukin 6 receptor β) (He, Gong et al. 2005), which is a regulator 
of PTPN11 (Schiemann, Bartoe et al. 1997).  
 
NUMB contains a phosphotyrosine-binding (PTB) domain and was shown to 
promote the ubiquitination of Notch1 receptor and controls Notch1 dependent 
signal transduction that has an important role in cellular differentiation, 
proliferation and apoptotic events during cell development (McGill and McGlade 
2003). It has been reported that the inhibition of EGFR signalling pathway could 
induce Notch1 activity (Kolev, Mandinova et al. 2008). With the silencing of NUMB 
gene, we would expect an accumulation of Notch1 receptor and that might have a 
negative feedback effect on the EGFR signalling pathway. Furthermore, Notch1 
have been suggested to interact with XRCC6 in a yeast two-hybrid screen (Stelzl, 
Worm et al. 2005). 
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Hit protein with no direct relationship with EGFR or CrkII 
FNBP1, C14orf1 and CDC42EP1 are all associated with CDC42 (Serebriiskii, Mitina et 
al. 2002; Stelzl, Worm et al. 2005)  but have no direct connection with EGFR. CYFIP1 
was shown to function as a Rac1-associated protein to from the WAVE1 complex 
and regulated actin filament reorganization (Kobayashi, Kuroda et al. 1998), MCF2 
(also known as DBL) is responsible for the guanine-nucleotide exchange factors 
activity (Zhu, Debreceni et al. 2000), but neither have an immediate connection to 
EGFR. There was also no indication of C9orf127, CD46, TRIO and ID2 associating 
being involved with the with EGFR or CrkII protein subnetwork. 
 
XRCC6, PDCD6IP and PTPN11 were selected for further validation to establish the 
biological importance of the genes identified as primary hits in the EGFR signalling 
network. Although we did not have time to do further validation due to the time 
limit within the project, it would be ideal to extract all the candidate hits from the 
library and perform an addition conformational screen. This screen should contain 
the pooled siRNA library to test the reproducibly of initial screen, and separately 
three of the individual sequence targeting the same gene to discriminate between 
effective and ineffective siRNAs. Knowledge of such genes will advance our 
understanding the role of EGFR in basal-like breast cancer, and help clarify some of 
the molecular mechanisms underlying the association between EGFR and poor 
clinical outcome. 
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In addition, we planned to generate cell-line with knockdown of EGFR and the 
identified hits from the FRET-FLIM screen. Using EGFR/c-MET inhibitors in parallel 
with the knockdown cell-lines we will determine the role of these tyrosine kinase 
receptors in preclinical basal-like breast cancer models.   
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Liposomal delivery system 
 
Another vital aspect of this project was to generate multifunctional serum-stable 
liposomes for targeted transfection of biosensor-encoding DNA and EGFR tyrosine 
kinase inhibitors, to address the liposomal potential on intratumoural activity 
sensing in murine models of basal-like breast cancer. The preparation, 
characterization, and optimization of the basic properties of liposomes were 
discussed in Result chapter 4.3. 
 
We presented a cellular and in vivo delivery system that was based on these 
nanoliposomes and use them as potential DNA and drug carriers. These synthetic 
liposomes were made of lipid bilayer composed of natural phospholipids and they 
were shown to be highly biodegradable and biocompatible in our cellular and 
animal models. A fraction of cholesterol was included in the formulations to 
modulate rigidity to increase stability both in vitro and in vivo applications, and to 
reduce serum induced instability caused by the binding of serum protein to the 
liposome membrane. Low concentration of cholesterol in the lipid bilayer can also 
lead to an increase in transmembrane permeability  (Lian and Ho 2001). 
 
The liposomes were also modified with hydrophilic polymer polyethylene glycol 
(PEG) to stabilise the liposome structures, decreasing their interactions with serum 
proteins and reducing inter-liposomes interaction to prevent aggregation. 
PEGylation of the liposome surface layer can prolong in vivo circulating time in 
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systemic circulation compared to non-modified liposomes, which enhances the 
opportunity to target tumours. The PEGylation liposomes also have a lower 
tendency to be rapidly cleared and degraded by cells of the mononuclear phagocyte 
system results in improved biodistribution (Varga, Wickham et al. 2000; Lian and Ho 
2001; Maruyama 2002; Grosse, Tagalakis et al. 2010). 
 
Another important surface modification in the development of the liposome was 
the attachment of EGFR-targeting peptides for active targeted delivery. We have 
shown that small structural differences in the selection of peptide sequence for 
receptor recognition could result in pronounced differences in liposomal uptake 
and DNA transfection when we compared the fluorescence emission signals. It has 
been recognised that the installation of targeting peptides could lead to more 
efficient internalization via receptor-mediated endocytosis and consequently higher 
transfection efficiency (Mustapa, Bell et al. 2007; Kudsiova, Fridrich et al. 2011). The 
liposomal formulations were optimised in the cellular transfection system with the 
selection of cell model, EGFR-targeting peptide sequence and peptide:DNA ratio to 
facilitate the optimal EGFR specific receptor-mediated transfection. 
 
We then applied the liposomes intravenously into established xenograft models of 
basal-like breast cancer (MDA-MB-231 and HCC1954), however, the in vivo 
transfection efficiency in both models was still suboptimal despite the efforts in 
cellular surface modification and optimisation experiments. However, this was 
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sufficient for us to sample the intratumoural heterogeneity in EGFR activity at a 
single cell level. 
 
In theory, liposomal nanoparticles with a size of several hundred nanometres could 
leak preferably throughout the tumour vasculature as their sizes were close to the 
vascular opening, therefore liposomes would passively accumulate in the tumour 
region based on the ‘enhanced permeability and retention (EPR) effect’, (due to 
poorly-aligned defective endothelial cells with wide fenestrations in newly formed 
vasculature in tumours, and the lack of effective lymphatic drainage), while passage 
is restricted by tight cellular junctions in normal tissue (Yuan, Dellian et al. 1995; 
Drummond, Meyer et al. 1999; Park and Yoo 2010; Prabhakar, Maeda et al. 2013). 
However, significant heterogeneity of EPR and hence differences in vessel structure 
(in terms of leakiness), both within a single tumour type (at different sites) and 
between tumour types, exists and may account for differences in transfection 
efficiencies of these liposomal nanoparticles (Prabhakar, Maeda et al. 2013). 
 
All LPD complexes used for the in vivo experiments were under 170nm in size (see 
appendix for dynamic light scattering (DLS) for nanoparticle size analysis). We 
hypothesised the reason for poor in vivo transfection was due to the poor blood 
supply in these solid tumour models, and therefore the liposome complex could not 
access freely to the tumour tissue.  
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In this regard, we also repeated the experiment using a highly vascularised human 
colorectal carcinoma SW1222 model (Zhang, Laufer et al. 2009) in order to achieve 
better rate of liposomal uptake; however, the number of tumour cells observed 
with the expression of transfected sensor did not improve. The low transfection 
rates could be due to a number of other reasons, such as high intestinal uptake or 
degradation of LPD complex with the mononuclear phagocyte system in liver and 
spleen; as well as DNA instability in bloodstream or poor tumour targeting and 
tissue accessibility of the liposome with inefficient release of DNA into the tumour 
cells. All of these factors also contribute to the observed low transfection of 
biosensor. The fate for the liposome is yet to be determined. Future in vivo imaging 
experiments using liposomes packed with radiotracer will allow us to characterise 
the pharmacokinetics of these LPD complexes. Further optimisation steps are 
required to formulate a serum-stable liposome for effective and specific delivery of 
the FRET-based sensor DNA. 
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Despite the difficulty of in vivo transfection, a small fraction of liposomes have 
distributed to the primary tumours where rapid tumour growth occurred. We 
managed to obtain enough biosensor-transfected cells in multiple tumour sections 
for the study of intratumoural EGFR activity and demonstrated a significant degree 
of heterogeneity of EGFR activity within the tumour microenvironment.  
 
The result showed a correlation between the sensor activities and distance to blood 
vessels in the MDA-MB-231 model, whereas the EGF-receptors were more active 
when cells were near the blood vessels. These results might explain the 
intratumoural heterogeneity of EGFR activity demonstrated by the FRET-based 
sensor. Here we suggested that EGFR activity might not always increase when 
tumour cells associated with macrophages, but only with those macrophages that 
were close to the circulation that had an elevated level of EGF secretion to facilitate 
migration and intravasation of tumour cells. An alternative mechanism that is being 
explored to account for the observed intratumoural heterogeneity of EGFR activity, 
within the supervisor’s laboratory, is the effect of hypoxia (one of the parameters 
that will depend on diffusion distances between the blood vessels and the tumour 
cells) (Vaupel and Harrison 2004) on the Picchu-X sensor activity. Hypoxia will in 
turn influence the reactive oxygen species production in cancers which through 
pyruvate kinase M2 (Anastasiou, Poulogiannis et al. 2011), may lead to a redox 
regulation of EGFR activity with the production of hydrogen peroxide (H2O2) 
(Paulsen, Truong et al. 2012; Truong and Carroll 2012). 
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Our FLIM measurement of the Picchu-X biosensor activity also demonstrated the 
inhibitory effect of EGFR tyrosine kinase inhibitor, Morpholino-IPQA, on the EGFR 
activity in the primary tumour of the established HCC1954 model. 
 
Furthermore, current trends and developments of nanoparticle delivery systems 
are designed on drug or gene delivery alone. The original goal was to develop 
liposomes that can carry both inhibitor and biosensor-encoding DNA, which was 
referred as a theragnostics approach, meaning the combination of therapeutics and 
diagnostics. As it has come to the end of the project; time did not allow us to 
continue with the development of such LPD-drug complexes that can carry both 
EGFR kinase inhibitors for targeted drug therapy, and sensor-encoding DNA for 
monitoring EGFR kinase activity. 
 
However, further experiments are planned in Alethea Tabor’s laboratory to label 
the anti-EGFR inhibitor with radioiodine (I125) and deliver it via the liposome for 
SPECT imaging.  DNA will be delivered in a separate liposome solution and tumours 
will be harvested to correlate the radioiodine standard uptake value (SUV) with the 
EGFR biosensor activity, to provide the definitive evidence that the radionuclide-
labelled tyrosine kinase inhibitor binding will influence the RTK activity of EGFR in 
these tumour cells. 
 
Iodine-labelled Morpholino-IPQA has previously been used as a radiotracer for the 
PET imaging of EGFR-overexpressing A431 human tumour xenograft grown in 
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immunocompromised animals. Although it successfully reflected a high level of 
EGFR expression and activity in A431 tumour cells, it exhibited a rapid hepatobiliary 
clearance rate of the radiotracer (Pal, Glekas et al. 2006). With the help of 
liposomal encapsulation of the radio-labelled inhibitor, it should allow higher 
cumulative concentration and better radiotracer uptake/retention in the EGFR-
expressing tumour. 
 
Medina et al. compared the pharmacokinetics and tumour targeting of the 
Morpholino-IPQA with that of the same tracer embedded in liposomes (Medina, 
Pillarsetty et al. 2011). Liposomal Morpholino-IPQA demonstrated an improved 
blood circulation time and a 3 to 6-fold increase with the tumour uptake. One 
problem with Morpholino-IPQA is that it is an amphiphilic compound; it will 
eventually leak out from the liposomes. Medina et al. reported an inhibitor release 
rate from the liposomes of 2.5%/hour. The in vivo imaging experiments with 125I-
Morpholino-IPQA and liposomally delivered Picchu-X sensor, that are aimed to 
demonstrate the relationship between the 125I-drug concentration at the target site 
(tumour) and the corresponding intratumoural EGFR activity in situ, are being 
carried out in the supervisor’s laboratory. It would also be ideal to test the release 
rate of our liposomal drug in future experiments and avoid prolonged storage. 
 
This work highlights the advantages of liposomal delivery of biosensor to monitor 
sub-cellular activity in the primary tumour. In addition, this method might also be 
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adapted to assess EGFR activity at the secondary sites of metastasis using these 
highly metastatic models of cancer. 
 
In the past six years, in the cancer domain, there have been large numbers of drug 
failures at the Phase III and submission stages; particularly with molecule-targeted 
drugs that have novel mechanisms of action but have relatively poor response rates 
in unselected patient population (Arrowsmith 2011).  In an attempt to improve this 
poor response, the United States Food & Drug Administration (FDA) published 
guidelines that linked approval of molecularly targeted drugs with identification and 
use of diagnostic tests that select patients most likely to benefit from the drug. To 
date, only 17 such therapeutic-‘companion diagnostic’ combinations have been 
approved, of which 14 are indicated for stratifying cancer patients for anti- Human 
Epidermal Growth Factor Receptor therapies. The prediction of response to HER 
therapy (such as Panitumumab and Cetuximab) on the basis of EGFR expression and  
specific mutations (KRas/BRAF/PIK3CA/PTEN), as a positive and negative predictor 
of therapeutic response, respectively (Bardelli and Siena 2010; De Roock, De 
Vriendt et al. 2011); is beginning to be translated into clinic (e.g. the DAKO EGFR 




However, the improvement of patient survival by stratification on the basis of EGFR 
expression and specific mutations alone has been disappointing low (e.g. only 10-
| - 199 -  
 
  
20% of chemotherapy-refractory CRC patients whose tumours express EGFR 
actually respond and, from these a large percentage will develop resistance and 
eventually relapse (Saltz, Meropol et al. 2004). It is our hope that the work begun in 
this thesis may lead to the clinical use of in vivo transfected fluorescence lifetime 
based biochemical sensors. These sensors will provide a more accurate readout of 
the sensitivity of tumour cells to EGFR inhibition, than receptor expression alone, 
among the heterogeneous patient population.  







CHAPTER 7: Appendix 
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Material and Method from Dr Nick Mitchell 
 
Development of a Theranostic Liposomal Delivery System for targeted Drug 
Treatment and FRET-based Biosensing of EGFR Activity 
 
Materials and Methods - Synthesis of lipids and preparation of liposomes. 1,2-
dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) was purchased from Avanti 
Polar Lipids Inc. (Alabaster, AL). All other reagents were purchased from Sigma-
Aldrich Co. Ltd. unless otherwise stated, and used without further purification. All 
reagents were of commercial quality and used as received and all solvents 
anhydrous. Thin Layer Chromatography (TLC) was performed on aluminium backed 
Sigma-Aldrich TLC plates with F254 fluorescent indicator. Visualisation was done by 
quenching of UV fluorescence or by staining the plates with potassium 
permanganate solution [KMnO4 (1.25 g), Na2CO3 (6.25 g), water (250 mL)]. Normal 
phase flash chromatography was carried out using silica gel (43–60 μm) supplied by 
Merck. LC/MS was performed on a Waters Acquity uPLC SQD using HPLC grade 
water and acetonitrile (both with 0.1% formic acid) as the solvents. MALDI MS was 
performed on a Waters MALDI MicroMX machine using α-cyano-4-hydroxycinnamic 
acid (CHCA) or sinapinic acid (SA) as the matrix (1 mg/mL in methanol). NMR (1H 
and 13C as performed on either 500 or 600 MHz AMX Bruker Spectrometers (as 
stated). The chemical shifts (δ) were given in units of ppm relative to 
tetramethylsilane (TMS), where δ (TMS) = 0 ppm. Coupling constants (J) were 
measured in Hertz (Hz), multiplicities for 1H coupling are shown as s (singlet), d 
(doublet), t (triplet), m (multiplet), or a combination of the above. Deuterated 
chloroform (CDCl3), dimethylsulfoxide (d6-DMSO) and methanol (CD3OD) were 
used as solvents (as stated) for all NMR analysis. Dynamic light scattering and zeta 
potential measurements were performed using a Malvern Zetasizer Nano-ZS 
(Malvern, UK).  
 




dimethyl-2,3-bis((Z)-octadec-9-enyloxy)propan-1-aminium (DODEG4) was 
synthesised as previously describedi as was N,N,N-trimethyl-2,3-bis((Z)-octadec-9-













To 1.35 g (2.18 mmol) of N,N-dimethyl-2,3-bis((Z)-octadec-9-enyloxy)propan-1-
amine in acetone was added 1.04 g (4.36 mmol) of tert butyl 3-bromopropyl-
carbamate (also in acetone - synthesised as described; J. Med. Chem. 2010, 6608-
6617) and the solution heated in a sealed tube at 100 °C for 48 hrs. After this time 
the solvent was removed under reduced pressure and the crude dissolved in 10 mL 
of a 1:1 solution of TFA:H2O and stirred at room temp. for 3 hrs. The solvent was 
again removed and the crude material purified via silica column chromatography 
using a solvent system of 5 – 20 % methanol in DCM. The fractions containing the 
pure product were pooled and the solvent removed under reduced pressure. The 
salt was then washed with sat. NaHCO3 (5mL) and extracted into CHCl3 (10mL), 
dried (Na2SO4) and concentrated. The resulting oil was dried under high vacuum to 
give 1.15 g (78% yield) of the desired product. Rf 0.39 (20% MeOH in CH2Cl2); vMAX 
(CHCl3)/cm-1 2923, 2854, 1678; ESI-HRMS found 677.6918 m/z [M+H]+, 
C44H89N2O2 requires 677.6924; 
1H NMR δH (600 MHz, CDCl3): 0.86 (t, 6H, J = 7.1 Hz, 
CH2CH3), 1.24-1.31 (m, 44H, CH2), 1.53 (m, 4H, CH2CH2O), 1.82-2.00 (m, 
10H, CH2CHCHCH2 and NCH2CH2CH2NH2), 3.36-3.72 (m, 19H, CH2OCH2CH 
CH2N(CH3)2 and  NCH2CH2 CH2NH2), 4.01 (2x bm, 1H, OCH2CHCH2N(CH3)2), 5.30-
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5.36 (m, 4H, CH2CHCHCH2); 
13C NMR (150 MHz, CDCl3) δ /ppm 14.25, 20.94, 22.81, 
25.13, 26.07, 26.12, 26.24, 27.35, 27.74, 29.21-30.07 (signals superimposed), 32.01, 
32.76, 33.82, 36.75, 39.33, 50.99, 51.64, 53.20, 59.27, 63.19, 66.37, 68.63, 69.47, 























1 mg of Cy5-NHS (1.26 umol) in DCM and 2 uL (15.2 umol) of triethylamine were 
added to 1.2 mg (1.52 umol) of the starting lipid also in DCM and allowed to react 
at room temperature overnight in the dark. After this time the solvent was 
removed under reduced pressure and the crude product purified via preparative 
TLC using a solvent system of 20% methanol in DCM to give 1.8 mg of the desired 
product (90% yield, one spot on TLC). TLC analysis; Rf = 0.63 (solv. sys.; 20% 
methanol in DCM); MALDI MS; calculated mass - 1314 g.mol-1; observed mass – 
1315 g.mol-1 (MH+); matrix; sinapinic acid (1 mg/mL in methanol).  
 
  
| - 204 -  
 
  










To 2.5 g (17.3 mmol) of fumeric acid monoethyl ester, 7.9 g (20.8 mmol) of HBTU 
and 6 mL (4.45 g, 34.4 mmol) of DIPEA in anhydrous DCM was added 2.5 g (17.3 
mmol) of N-(3-aminopropyl) morpholine. The reaction was allowed to stir at room 
temp. and over the following 3h a further 0.15 eq of N-(3-aminopropyl) morpholine 
and DIPEA was added. After this time the solvent was removed under reduced 
pressure and the crude oil purified via flash chromatography to give 3.41 g of the 
desired product (73% yield). LC/MS; calculated mass 270.16 g.mol-1 (C13H22O4N2); 
observed mass 271.5 m/z (MH+).1H NMR (500 MHz, CDCl3) δ /ppm 1.3 (3H, t, J = 
7.17, ethyl gp), 1.7 (2H, q, J = 6.31, -CH2-), 2.5 (6H, m), 3.45 (2H, m, -CH2-), 3.7 (4H, t, 
J = 4.57, -OCH2-), 4.2 (2H, q, J = 7.10, ethyl gp.), 6.8 (2H, dd, J = 15.61, alkene), 7.5 
(1H, s, -NH-). 13C NMR (125 MHz, CDCl3) δ /ppm 14.21, 24.25, 39.70, 53.57, 57.72, 









25 mL (22.4 g, 188.2 mmol) of N,N-dimethylformamide dimethyl acetal was added 
to 10.23 g (62.7 mmol) of 5-nitroanthranitrile. The solution was refluxed at 100 °C 
for 4.5h then filtered. The orange solid was washed with diethyl ether and dried in a 
desiccator to give 12.52 g (91.6%) of the desired product. LC/MS; calculated mass 
218.08 g.mol-1 (C10H10O2N4); observed mass 219.2 m/z (MH
+).1H NMR (500 MHz, 
CDCl3) δ /ppm 3.15 (6H, s, N(CH3)2), 7.0 (1H, d, J = 9.06, aromatic), 7.7 (1H, s, imine), 
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8.2 (1H, dd, J = 2.68, aromatic), 8.4 (1H, d, J = 2.68, aromatic). 13C NMR (125 MHz, 











75 mL of acetic acid was added to 5 g (22.9 mmol) of (E)-N'-(2-cyano-4-nitrophenyl)-
N,N-dimethylformimidamide and 6 g (3.32 mL, 27.6 mmol) of 3-iodoanaline. The 
reaction was refluxed at 125 °C until it reached completion. The solution was stored 
at 4 °C overnight and the resulting precipitate filtered and washed with diethyl 
ether. The yellow solid was dried in a descicator to give 10.32 g (88.2% yield) of the 
acetate salt product. No further purification was necessary. 2.5 g ( mmol) of this 
product was dissolved in 50 mL ethanol, 10 mL distilled water and 5 mL acetic acid 
and refluxed at 100 °C for 15 min. After this time 5 g of Fe powder was washed with 
1N HCl and distilled water and suspended in distilled water. The slurry was added 
slowly using a dropping funnel and the reaction allowed to reflux using a 
mechanical stirrer. After 2h the reaction was filtered through celite the filtrate was 
diluted up in ethyl acetate and to this solution conc. HCl was added dropwise. The 
HCl salt of the amine crashed out of solution and was filtered. Further c.HCl was 
added to the filtrate and the process repeated. The solid was dried in a desiccator, 
redissolved in distilled water, basified with 1M NaOH and extracted into DCM. The 
organic phase was dried over MgSO4 and the solvent removed under reduced 
pressure to give 1.32 g of a dark brown solid. LC/MS; calculated mass 362.00 g.mol-
1 (C14H11N4I); observed mass 363.3 m/z (MH
+).1H NMR (500 MHz d6-DMSO) δ /ppm 
5.6 (2H, bs, NH2), 7.1 (1H, t, J = 7.95), 7.2 (1H, d, J = 7.50), 7.35 (2H, m), 7.5 (1H, d, J 
= 8.75), 8.34 (1H, s), 8.35 (1H, s), 9.4 (1H, bs, -NH-); 13C NMR (125 MHz, d6-DMSO) δ 
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/ppm 30.69, 94.13, 100.96, 116.71, 120.59, 123.77, 128.70, 129.31, 130.35, 131.04, 
141.61, 142.66, 147.39, 149.58, 155.70. 
 












0.5 g of compound 15 was dissolved in 20 mL of distilled water and 1 mL of 
triethylamine added. The solution was allowed to stir at room temp. overnight. 
After this period the solvent was removed under reduced pressure and the oil dried 
on a high vacuum line overnight. To 0.729 mmol of the acid (0.250 g) in anhydrous 
pyridine was added 0.154 mg (0.802 mmol) of EDC also in pyridine. 0.266 g (0.729 
mmol) of compound 17 in dry pyridine was then added to the reaction which was 
left stirring under Ar(g) for 2h. After this time a further 0.5 eq. of EDC (70 mg) was 
added and the reaction left strirring for another overnight. The solvent was then 
removed under reduced pressure the crude was purified by silica gel 
chromatography using a solvent system of 0 – 10% methanol in DCM (material dry 
loaded onto the column) to afford 153 mg of the desired product (36% yield). To 
generate the water soluble TFA salt the compound was eluted through a semi-prep 
HPLC column (Phenomenex C18) using a gradient of 2 – 40 % acetonitrile (0.1% TFA) 
in HPLC grade water (0.1% TFA) over 20 min. Fractions containing the desired 
product were combined and the solvent removed under reduced pressure. The 
material was redissolved in 5 mL of distilled water and freeze-dried overnight. 
LC/MS; calculated mass 586.12 g.mol-1 (C25H27O3N6I); observed mass 587.3 m/z 
(MH+). 1H NMR (500 MHz MeOD) δ /ppm 2.0 (2H, m), 3.1 (4H, m), 3.4 (2H, m), 3.5 
(2H, m), 3.8 (2H, m), 4.0 (2H, m), 7.1 (2H, dd, J = 15.05), 7.25 (1H, t, J = 7.49), 7.7 
(2H, dd, J = 8.0), 7.85 (1H, d, J = 8.91), 8.1 (1H, d, J= 8.91), 8.2 (1H, s), 8.7 (1H, s), 9.0 
(1H, s). 13C NMR (125 MHz, MeOD) δ /ppm 14.0, 24.6, 37.1, 52.8, 55.7, 64.7, 93.8, 
113.5, 121.0, 124.7, 130.3, 133.5, 135.1, 136.9, 138.7, 140.1, 150.6, 166.6.       
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General method for solid phase peptide synthesis (SPPS). All peptides were 
synthesized using standard Fmoc solid-phase peptide synthesis on a Syro 
automated system. Pre-loaded Wang or TGT resin was used with standard 
HBTU/DIPEA coupling chemistry. All amino acids were purchased as N-protected 
Fmoc and appropriately protected R group compounds. Each coupling step was 
conducted for 40 mins and each Fmoc deprotection allowed to proceed for 3 min in 
40 % piperdine and then 10 min in 20% piperidine. Four equivalents of amino acids 
and associated reagents were used. After completion of the synthesis, peptides 
were deprotected and cleaved from the resin by incubation in TFA/TES/EDT/H2O 
(2500:150:75:150 μL) for 3 hours. The collected peptide solution was mixed with 
diethyl ether and allowed to precipitate at -20°C. The suspension was centrifuged at 
4000 rpm for 5 min, and the pellet was re-dissolved in diethyl ether. This 
purification process was repeated three times after which the precipitate was 
dissolved in deionized H2O or 0.1% TFA containing HPLC grade water if necessary, 
frozen in liquid N2 and freeze-dried overnight. The peptides were analyzed and if 
necessary purified via reversed phase HPLC using a Varian ProStar system with a 
Model 210 solvent delivery module and a Model 320 UV detector. The preparative 
purification was performed using either a Varian preparative column (C18, 250 x 
21.2 mm, 10 μm beads, flow rate of 10 mL/min) or Phenomenex semi-prep (C18, 
100 x 10 mm, flow rate of 8 mL/min). The mobile phase was a linear gradient 
beginning with 98:2 water (0.1% TFA) / acetonitrile (0.1% TFA) to 2:98 water (0.1% 
TFA) / acetonitrile (0.1% TFA) over 30 min, this gradient was adapted when 
necessary. Fractions containing the correct peak were pooled, the solvent removed 
under reduced pressure to approximately 5 mL, and the solution freeze-dried 
overnight. ESI-MS analysis was performed on a Waters Acquity Ultra Performance 
LC/MS machine in positive ion mode using the same solvent system and gradient as 
the analytical HPLC procedure detailed above (0.6 ml/min, 0.1% formic acid used in 
place of TFA).  
 
  






























































































































































Formation of LPD complexes. All lipid components were dissolved in either CHCl3 
or methanol to a concentration of 1 mM. The lipids were mixed together in the 
appropriate molar ratios (CH300 50 mol%, DOPE 30 mol%, DOTMA 20 mol%, 
Cholesterol 30 mol% - if Cy5 lipid used then replaces 1 mol% of DOPE) and the 
solvents removed under reduced pressure to form a thin film. This film was further 
dried on a high vacuum line for 4 h (or overnight in a desiccator) then hydrated with 
sterilized water. For in vitro samples the formulations were sonicated using a bath 
sonicator for 10 mins. A total lipid conc. of 100 uM was favoured; 4 – 16 ug of 
peptide was added to the liposome solution followed by 1 – 4 ug of plasmid DNA 
(Picchu biosensor), the samples were then used immediately. For in vivo samples the 
formulations were prepared using a probe sonicator (Sonifier SLPe, Branson (USA)). 
A total lipid conc. of 1.5 mM was used with addition of 136 ug mg of K16 peptide 
(or equal molar amount if alterative sequences were used) and 68 ug of DNA per 
injected sample. The peptide (in sterilized water) was added to the liposome solution 
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and diluted to 2 mL. The appropriate volume of DNA solution (also in sterilized 
water) was also diluted to 2 mL and combined with the LP solution. The samples 
were then concentrated to an appropriate volume for injection using VivaSpin 
columns (MWCO 10,000). The liposomes were characterized using DLS and Zeta 
potential; aliquots of  
25 – 50 uL were diluted to 1 mL in sterilized water and analysed in triplicate at 25 




Table 1; (1) Liposome sample; (2) LPD Picchu-X plasmid + P2; (3) LPD GFP 




Liposome  DODEG-4 DOPE DOTMA Cy5-L Cholesterol DLS (PDI) Zeta pot. 
        
In vitro 50% 29% 20% 1% 30% - - 
In vivo (1) 50% 30% 20% 0% 30% 146.3 nm (0.264) 52.4 mV 
In vivo (2) 50% 30% 20% 0% 30% 147.1 nm (0.355) 40.6 mV 
In vivo (3) 50% 30% 20% 0% 30% 140.2 nm (0.407) 56.7 mV 
In vivo (4) 50% 30% 20% 0% 30% 85.7 nm (0.274) 44.8 mV 
In vivo (5) 50% 30% 20% 0% 30% 168.5 nm (0.3) 33.1 mV 
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